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ABSTRACT 
 
 
 
The seasonal termination of ovarian cycles in mares initiated near the time of the 
autumnal equinox is a significant managerial issue for horse breeders world-wide. 
Studies presented herein had two over-arching aims. In Aim I, objectives were to 
develop the principals needed to apply gonadotropin-releasing hormone (GnRH) 
therapeutics for routinely establishing pregnancies in the winter anovulatory mare. We 
first tested the hypothesis that continuous administration of native GnRH, beginning in 
either early February or March, would induce ovulation without reversion to an 
anovulatory state following treatment withdrawal. Continuous 28-d treatments elevated 
circulating luteinizing hormone (LH) and stimulated spontaneous ovulation much earlier 
than controls. However, mares treated only in February ceased ovarian cycles at 
termination of treatment. In contrast, mares administered GnRH in March continued to 
exhibit estrous cycles. Thus, we concluded that GnRH treatment must continue through 
March to ensure continued escape from winter anovulation. We then tested the 
hypothesis that the Julian day of conception could be accelerated in winter anovulatory 
mares treated continuously with native GnRH for 56 d beginning on February 1. Indeed, 
GnRH treatment caused a marked increase in the frequency of pregnancy compared to 
controls. Data illustrated that continuous administration of native GnRH is a practical 
and highly efficient option for managing seasonal anovulation. In Aim II, we examined 
hypothalamic distribution, adenohyphyseal receptor gene expression, and ligand 
functionality of RFRP3 in the mare during the breeding and non-breeding seasons. 
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Hypothalamic RFRP3 mRNA was detected in the mare; however, neither hypothalamic 
expression of RFRP3 nor its anterior pituitary receptor differed between reproductive 
states. We then used equine adenohypophyseal cell culture to test the hypothesis that 
RFRP3 reduces the responsiveness of the equine gonadotrope to GnRH. Addition of 
RFRP3 to cell culture failed to counter the effects of GnRH. Finally, the effects of a 
RFRP3 receptor-signaling antagonist (RF9) were examined in winter anovulatory mares. 
A robust increase in circulating concentrations of LH relative to controls was observed 
in response to RF9 treatments, but treatments had no effect on adenohypophyseal 
responsiveness to GnRH. Data provide indirect evidence that antagonism of the RFRP3 
system by RF9 may be at the GnRH neuronal level.  
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CHAPTER I 
INTRODUCTION 
 
 
 
Reproductive seasonality in the mare is characterized by an abrupt and marked 
decline in adenohypophyseal synthesis and secretion of luteinizing hormone (LH) near 
the autumnal equinox (Ginther, 1992). This results ultimately in the cessation of ovarian 
cycles in at least 85% of standard horse mares by the time of the winter solstice. 
Resumption of normal anterior pituitary and ovarian function follows approximately 3 to 
4 mo later (Ginther, 1992). Length of the winter anovulatory season can be reduced by 
1) provision of supplemental lighting beginning near the winter solstice to extend day-
length to 15 to 16 h (Ginther, 1992), or 2) treatment with native gonadotropin-releasing 
hormone (GnRH) to stimulate synthesis and secretion of LH (Johnson, 1987; Becker and 
Johnson, 1992). Currently, the provision of supplemental lighting is the only practical 
option available to the equine industry. 
Johnson (1987) first demonstrated that hourly intravenous injections of native 
GnRH to anovulatory mares in January, at doses as low as 2 µg/h, rapidly increase 
circulating concentrations of LH, stimulates follicular development, and causes 
spontaneous ovulation within 2 wk. Similar but delayed responses were attained using 
continuous subcutaneous infusions (Hyland and Jeffcott, 1988; Becker and Johnson, 
1992); however, 10 to 30-fold greater doses of GnRH were required to elicit a LH 
response. Importantly, and in contrast to effects in other species, continuous treatment of 
mares with native GnRH at dose rates as great as 250 μg/h does not result in pituitary 
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desensitization (Porter et al., 1997). Therefore, continuous, high-dose infusions of native 
hormone remain functionally stimulatory in the horse. These relationships do not hold 
true for synthetic, long-acting GnRH agonists (Fitzgerald et al., 1993; Mumford et al., 
1994) which, when given continuously, result in pituitary desensitization. Thus, the 
decision by the industry to focus primarily on synthetic agonists for commercially-
targeted applications, while optimizing proprietary potential, have failed as practical 
therapeutic agents in the transitional mare. 
From a purely endocrine perspective, data support the hypothesis that reductions 
in hypothalamic GnRH release during the winter anovulatory period account for the 
characteristic reduction in synthesis (Hart et al., 1984) and release (Sharp & Grubaugh, 
1987) of LH during this period. However, Cooper et al. (2006) measured GnRH 
secretion patterns in pituitary venous effluent of mares during 4 seasons using the 
intercavernous sinus (ICS) cannulation technique, yielding results that contradict 
existing dogma. Results indicated that ICS concentrations of GnRH, and the frequency 
and amplitude of GnRH pulses, were invariant across seasons. Thus, although contrary 
to accepted dogma, it is possible that the reduction in secretion of LH occurring about 
the time of the autumnal equinox may not be regulated solely through reduced 
endogenous secretion of GnRH. Velez et al. (2008) demonstrated that the anovulatory 
mare is less responsive to GnRH following the winter solstice than during the period just 
before or at the winter solstice. Thus, it was concluded that the length of exposure to a 
non-permissive photoperiod has a greater negative impact on adenohypophyseal 
responsiveness to GnRH than absolute day-length at the time of GnRH treatment. 
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However, it remains unclear as to whether this is a consequence of a longer period of 
deficits in GnRH stimulation or maximal effects of a negative modulator of gonadotrope 
function. 
Mechanisms through which gonadotrope function could be impeded during 
winter anovulation have not been determined in the mare. However, it could include 
effects mediated through a recently-discovered neuropeptide family, arginine 
phenylalanine-amide related peptide (RFRP). Members of the RFRP family have been 
linked to reproductive seasonality in seasonal breeding birds and some mammalian 
species, with marked changes in RFRP gene expression and peptide accumulation in the 
hypothalamus with changing photoperiod (Tsutsui et al., 2000; Ubuka et al., 2005; 
Clarke et al., 2008; Revel et al., 2008). In birds, one RFRP sequence (RFRP3) has now 
been termed gonadotropin-inhibiting hormone (GnIH). The latter directly suppresses 
secretion of LH and adenohypophyseal responsiveness to GnRH in birds and several 
mammalian species (Tsutsui et al., 2000; Kriegsfeld el al., 2006). Therefore, it is 
possible that an equine homolog of this peptide could play a major role in negatively 
regulating reproductive seasonality in the mare. 
This dissertation consists of two over-arching aims as it relates to the stimulatory 
(GnRH) and inhibitory (RFRP3) control of the reproductive neuroendocrine axis of the 
mare. The first over-arching aim consists of experiments designed to better understand 
the ability of continuously-administered, native GnRH to regulate adenohypophyseal 
function during the winter anovulatory period. This information will then be used to 
optimize practical procedures for the commercial use of GnRH to manage seasonal 
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anovulation in a North American management setting. In the second over-arching aim, 
we examined hypothalamic distribution, adenohyphyseal receptor gene expression, and 
ligand functionality of RFRP3 in the mare during the breeding and non-breeding 
seasons. These data will provide the groundwork for intervention strategies utilizing 
antagonists of the RFRP3 signaling cascade to disinhibit the effects of an inhibitory 
photoperiod in the winter anovulatory mare.  
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CHAPTER II 
REVIEW OF LITERATURE 
 
 
 
2.1 Neuroanatomical tracts underlying seasonality in the horse 
The control of reproductive seasonality in mammals is ultimately regulated by 
the environmental cue of photoperiod. In mares, photoperiod is recognized by retinal 
photoreceptors and transmitted as neuronal signals along the optic nerve, decussate at the 
optic chiasm to reach the supra chiasmic nuclei (Sharp et al., 1984) and superior cervical 
ganglia (Sharp et al., 1979), and eventually modulate function of the pineal gland 
(Goldman, 2001). Pinealocytes intercept this neuronal signal as exocytosed 
norepinephrine that binds to cellular membrane-bound β-adrenergic receptors (Hadley & 
Levine, 2007). Upon receptor binding, intracellular mechanisms convert tryptophan to 
melatonin that can eventually be released into the surrounding capillary network or 
cerebrospinal fluid. 
 
2.2 Melatonin synthesis 
Mechanisms that regulate melatonin synthesis within the pinealocyte begin with 
the conversion of tryptophan to serotonin via enzymatic conversion by tryptophan 
hydroxylase and aromatic amino acid decarboxylase (Young and Anderson, 1982). 
Interestingly, tryptophan hydroxylase activity is increased during the nocturnal period 
(Shibuya et al., 1978; Sitaram and Lees, 1978) allowing for increased melatonin 
production. Serotonin is then enzymatically converted to N-acetylserotonin via 
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serotonin-N-acetyltransferase (SNAT). Similar to tryptophan hydroxylase, 
concentrations of SNAT are very low within the pineal gland during the day (Buda and 
Klein, 1978). Nocturnally, SNAT activity is increased by norepinephrine released from 
neuronal terminals that synapse at the pineal gland (Buda and Klein, 1978). 
Norepinephrine also activates the intracellular pinealocyte adenylate cyclase-cAMP 
second messenger system through stimulation of membrane β-adrenoreceptors 
(Auerbach et al., 1981). Finally, hydroxy-indole-0-methyl transferase (HIOMT) 
enzymatically converts N-acetylserotonin to melatonin (Buda and Klein, 1978). 
Importantly, pineal concentrations of HIOMT remain elevated throughout the day 
(Reiter, 1991). Therefore, this enzyme is not believed to be rate limiting in biosynthesis 
of melatonin (Reiter, 1991). 
 
2.3 Melatonin control of reproductive seasonality 
Circulating concentrations of melatonin are entrained in a circadian rhythm, with 
the greatest concentrations observed during dark periods (Sharp & Cleaver, 1993). Thus, 
seasonal breeding species appear to perceive environmental cues through changes in 
circulating melatonin that influence reproduction; however, much debate surrounds the 
issue of melatonin action. In the horse, Nonno et al (1995) reported no melatonin 
receptors within the suprachiasmatic nucleus (SCN) as noted in other long-day breeders 
(Siberian hamster; Weaver et al., 1991; Reppert et al., 1994), short-day breeders (ewe; 
Bittman and Weaver, 1990), and rat (Reppert et al., 1994). Instead, it was suggested that 
seasonal influence is regulated through melatonin binding to receptors located in the pars 
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tuberalis, pars distalis, and pars intermedia, as 2-[125I] iodomelatonin binding is absent in 
the equine hypothalamus (Nonno et al., 1995). In contrast, Stankov et al (1991) reported 
low, but significant melatonin receptor content within the SCN, preoptic area (POA), 
and cortical regions. Further, these binding sites were of high affinity, low capacity and 
high specificity (Stankov et al., 1991). Localization of melatonin receptors within the 
SCN supports the finding that under constant exposure of light, ovariectomized pony 
mares have increased hypothalamic GnRH content and subsequently circulating 
concentrations of LH (Cleaver et al., 1991). However, while exogenous, subcutaneous 
administration of melatonin to ovariectomized pony mares during the breeding season 
reduced hypothalamic GnRH content (Strauss et al, 1979) it did not alter circulating LH 
concentrations in ovariectomized or intact pony mares (Peltier et al., 1997). The report 
of Strauss et al. (1979) can be interpreted to indicate that GnRH synthesis is reduced due 
to the effects of melatonin which may result in a similar decline in GnRH release. 
However, this does not address the failure of exogenous melatonin to suppress 
circulating concentrations of LH (Peltier et al., 1997) which would be interpreted to 
indicate that release of GnRH is not affected by melatonin. Instead, it suggests that an 
inhibitory modulator may be affecting gonadotropin synthesis and/or release which is in 
contrast to dogma indicating that a deficiency in GnRH synthesis and/or secretion is the 
central factor driving the demise of seasonal reproductive cyclicity (Hart et al., 1984; 
Grubaugh et al., 1982; Barrell et al., 1992; Irvine et al., 2000).  
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2.4 GnRH control of reproductive seasonality 
Secreted GnRH travels from the hypothalamus through the hypothalamo-
hypophyseal portal system targeting its G-protein coupled receptor on gonadotropes 
(Irvine & Alexander, 1993). Gonadotropin-releasing hormone receptor number is 
invariant across seasons in the mare (Hart et al., 1984). Upon GnRH binding to its 
receptor, the gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone 
(LH), are synthesized and secreted to induce ovarian follicular growth and ovulation. 
This mechanistic regulation of gonadotropes allows for the potential of therapeutic 
application of GnRH to modify reproductive cyclicity, particularly in the mare which is 
resistant to adenohypophyseal refractoriness upon continuous infusion of native GnRH 
(see below). 
 
2.5 Industry-induced problem 
With the establishment of the “official” birth date set as January 1 by the English 
Jockey Club in 1833 and subsequently adopted worldwide by the majority of modern 
breed associations, performance incentives are associated with earlier foaling because 
earlier foals are more mature during their early years of competition (Ginther, 1992; 
Langlois and Blouin, 1996). However, mares are seasonally polyestrous, with a period of 
reproductive competence occurring from approximately April to October (Northern 
Hemisphere). Thus, manipulation of the reproductive axis is required for foals to be born 
early in the calendar year (Ginther, 1992). Currently, only two options for hastening 
reproductive cyclicity exist in the winter anovulatory mare.  
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2.6 Methods to induce ovulation precociously 
2.6.1 Extend photoperiod 
The first, and most widely used option to hasten reproductive cyclicity is the 
supplementation of lighting beginning around the time of the winter solstice (December 
21) to artificially extend day-length to 15 to 16 h (Ginther, 1992). This methodology was 
first described by Burkhardt (1947) as an effective, noninvasive means to advance the 
breeding season. However, it is important to note that this treatment does not shorten, 
but merely advances the transition period (McCue et al., 2007) with interval from 
initiation of light supplementation to ovulation ranging from approximately 60 to 90 d 
(Ginther, 1992). Further, as light treatments require the interruption in endogenous, 
nocturnal melatonin secretion, this treatment must be 1) applied at dusk, reducing the 
period of darkness to 8 to 9 h (Burkhardt, 1947) or 2) applied for 1 to 2 h during the 
nocturnal photosensitive phase that begins from 8 to 9.5 h after the onset of darkness 
(Palmer et al. 1982; Malinowski et al. 1985; Gulliaume et al. 2000). Also, care must be 
taken when removing mares from supplemental lighting when ambient photoperiod is 
short, as mares may return to a winter anovulatory state (Scoggin et al., 2000) following 
induced ovulation. 
The second option to hasten reproductive cyclicity is the application of 
pharmacological treatments to stimulate the synthesis and secretion of LH by 
gonadotropes, increase circulating concentrations of exogenous gonadotropins or 
gonadotropin-like compounds, or enhance the ability of the ovary to respond to limited 
gonadotropic stimuli.  
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2.6.2 Prolactin 
Circulating concentrations of prolactin are inversely related to concentrations of 
melatonin, with the greatest concentrations of prolactin observed during the summer 
(Johnson, 1986; Thompson et al., 1986). In fact, recombinant porcine prolactin (rpPRL) 
induced rapid increases in circulating prolactin and follicular growth, while reducing 
mean interval to induced ovulation (21 d) in winter anovulatory mares (Thompson et al., 
1997). However, it has been proposed that large, exogenous doses of prolactin are acting 
at the level of the ovary to induce rapid follicular growth and ovulation (Nequin et al., 
1993; Thompson et al., 1997) and not on enhancing gonadotrope function. Further, 
Thompson et al (1997) reported that all rpPRL treated mares exhibited antibodies to the 
treatment by the 28th day of rpPRL injection. However, these studies were performed 
using a limited number of animals and recombinant equine prolactin treatments have not 
been pursued commercially. 
 
2.6.3 Dopamine antagonists 
As a means to circumvent antibody production, treatments that enhance 
endogenous prolactin secretion have been developed. One such method involves the 
administration of dopamine antagonists such as sulpiride and domperidone (Olin et al., 
1991). These compounds antagonize the suppressive effects of dopamine during the 
winter anovulatory period and allow for circulating concentrations of prolactin to 
increase (Cross et al., 1995). Unlike reports using rpPRL, results utilizing dopamine 
antagonists to enhance endogenous prolactin secretion are conflicting. Some 
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experiments reported only follicular growth (Nequin et al., 1993), whereas others have 
reported follicular development, shortened interval to ovulation, normal progesterone 
profiles, and fertile ovulations with large, daily doses (sulpiride, 200 mg/mare to 1 
mg/kg BW; Besognet et al., 1996; Besognet et al., 1997). However, all sulpiride treated 
mares that did not become pregnant, returned to winter anovulation. In contrast to the 
above observations, the same treatment (1 mg/kg BW) administered to mares in deep 
winter anovulation failed to stimulate follicle development or ovulation in spite of 
elevating circulating concentrations of prolactin (Donadeu and Thompson, 2002). 
Importantly, mares in this study were not maintained under artificial photoperiod as were 
the aforementioned studies. Interestingly, domperidone at a similar dose (1.1 mg/kg 
BW) was able to induce follicular growth, reduce the interval to ovulation, result in 
normal progesterone profiles, and elevate prolactin in deep winter anovulatory mares 
under ambient photoperiod (Brendemuehl and Cross, 1996; Brendemuehl and Cross, 
2000). Further, this treatment had no effect on FSH or LH secretion, yet 75% of treated 
mares continued to cycle following treatment withdrawal. It was hypothesized that 
dopamine antagonists allow for increased circulating concentrations of prolactin which 
may increase ovarian gonadotropin receptors, thus increasing responsiveness to an 
existing environment of low circulating concentrations of endogenous gonadotropins 
(Duchamp and Daels, 2002). In spite of the potential advantages of using dopamine 
antagonists to reverse seasonal anovulation in the mare, responsiveness to treatment has 
been inconsistent and seems to be dependent on depth of anovulation and the 
concomitant extension of photoperiod. The roles of other catecholamines, such as 
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norepinephrine and epinephrine, have not been thoroughly investigated in the 
anovulatory mare. However, these compounds have been indirectly implicated in 
reducing the secretion of GnRH during the non-breeding season using an α-adrenergic 
agonist (Xylazine) to increase pulse frequency of FSH and LH (Fitzgerald and Mellbye, 
1988). Therefore, catecholamine antagonists may serve some function in reversing 
seasonal anovulation. 
 
2.6.4 Endogenous opioid peptides 
Increased opioidergic inhibitory tone occurs during the non-breeding season and 
mares that ovulate spontaneously during the non-breeding season exhibit reduced opioid 
inhibition (Turner et al., 1995; Davison et al., 1998). In fact, blockade of this system 
through administration of the opioid antagonist naloxone increases the secretion of LH 
in the seasonally anovulatory mare (Aurich et al., 1994). Sharp et al. (1985) was not able 
to suppress secretion of LH using a large dose (2 mg/kg BW) of naloxone; however, this 
is most likely a function of the bell-shaped response curve of naloxone (Irvine et al., 
1994). Therefore, it is believed that opioids inhibit the hypothalamic pituitary axis of the 
mare during times of reduced photoperiod and this inhibition is reduced as the winter 
anovulatory mare transitions into the breeding season (Turner et al., 1995; Davison et al., 
1998). It has been demonstrated in other species that opioid-induced inhibition of LH 
secretion is regulated by inhibiting the secretion of hypothalamic GnRH (Cicero et al., 
1979; Kalra, 1981; Wilkes and Yen, 1981; Grossman et al., 1981) but this has not been 
confirmed in the mare.  
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2.6.5 Neuro-excitatory amino acids 
It has been proposed that insufficient GnRH neuronal stimulation drives the 
seasonal reduction in gonadal activity. To test this, Fitzgerald (1996) treated intact and 
ovariectomized mares during the non-breeding season with N-methyl-DL-aspartic acid 
(NMA) to stimulate neuro-excitatory amino acid receptors. This compound was able to 
stimulate secretion of gonadotropins in intact and ovariectomized mares. However, 
Fitzgerald and Davison (1997) concluded that neuro-excitatory amino acids do not play 
a role in seasonal regulation of reproduction as NMA resulted in a similar level of 
gonadotropin stimulation in ovulatory and anovulatory mares during the non-breeding 
season. Further, the large dose (5 mg/kg BW) of NMA required to induce sufficient 
gonadotropin secretion results in excessive excitability that put both mare and personnel 
in danger (Fitzgerald, 1996). 
 
2.6.6 Gonadotropins and gonadotropin-like compounds 
Use of equine pituitary extract (EPE) has proven highly effective (87 to 100%) in 
hastening follicular growth and ovulation induction in deep winter anovulatory mares 
(Douglas et al., 1974; Lapin and Ginther, 1977). However, Woods and Ginther (1982) 
demonstrated that treatment with EPE is more effective in late transitional mares as the 
interval from treatment onset to ovulation is reduced in mares with greater initial follicle 
size. Further two important factors need to be taken into consideration: 1) treatment with 
EPE requires more intense management as EPE results in multiple ovulations in 44 to 
58% of treated mares (Douglas et al., 1974; Woods and Ginther, 1982) and 2) 55% of 
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mares treated with EPE that failed to become pregnant returned to winter anovulation 
following treatment withdrawal (Woods and Ginther, 1982). In addition, EPE is not used 
in practice as a commercial source is not available and collection of equine pituitaries is 
difficult since U.S. equine slaughter facilities have been closed. Recently, recombinant 
equine gonadotropins (reFSH and reLH) and recombinant equine gonadotropin-like 
(recombinant equine chorionic gonadotropin; reCG) treatments have demonstrated 
promise for inducing follicular growth (reFSH; Jennings et al., 2009) and ovulation 
(reLH and reCG; Niswender et al., 2006; Yoon et al., 2007). However, published studies 
have not determined directly the ability of such treatments to induce follicular 
development and ovulation in the winter anovulatory mare. Meyers-Brown (2010) has 
demonstrated that concomitant treatment with reFSH and reLH shortens the interval to 
ovulation in transitional mares; however, a limited number of mares were utilized in this 
study and multiple ovulations were observed. 
 
2.6.7 Progesterone and progesterone combinations 
Conflicting evidence exists as to the efficacy of advancing first ovulation using 
natural and synthetic progesterone treatments in the winter anovulatory mare. It is 
known that progesterone treatments suppress the irregular periods of estrous behavior 
characteristic of the transitional mare (Turner et al., 1981) and advance the synchronous 
interval to first ovulation in transitional mares (Squires et al., 1979; Allen et al., 1980; 
Squires, 1993; Nagy et al., 1998a,b). However, progesterone treatments will not advance 
ovulation, consistently in the deep seasonally anovulatory or early transitional mare 
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(Squires et al., 1979; Allen et al. 1980; Turner et al., 1981; Alexander and Irvine, 1991). 
Further, the combined treatment of progesterone and estradiol 17-β is not more effective 
than progesterone alone (Wiepz et al., 1988). Therefore, as progesterone treatments are 
not consistently effective for initiating ovarian cyclicity in a majority of mares, the 
widespread acceptance of progesterone treatments have not been observed. 
 
2.6.8 Gonadotropin-releasing hormone 
It was first demonstrated by Johnson (1987) that intravenous administration of 
native GnRH in hourly pulses to anovulatory mares in January would result in increased 
circulating concentrations of LH, development of a preovulatory follicle, and in most 
cases spontaneous ovulation within 2 wk. This occurred at doses as low as 2 μg/h, when 
administered in hourly pulses. Similar responses could be attained using the continuous, 
subcutaneous route, but doses 10 to 50-fold greater were required to be effective (Becker 
and Johnson, 1992). Therefore, while existing dogma indicates that continuously-applied 
GnRH treatment does not down-regulate the GnRH receptor in horses, its pulsatile 
administration clearly optimizes gonadotrope responsiveness. However, the application 
of intravenous, pulsatile treatments are not practical for routine use; therefore, 
subcutaneous administration is a suitable alternative that elicits the desired gonadal 
response. This does not hold true for synthetic, long-acting GnRH agonists (Fitzgerald et 
al., 1993; Mumford et al., 1994; Farquhar et al., 2001). Further, withdrawal of GnRH 
agonist treatment following induced ovulation results in embryonic loss (Bergfelt & 
Ginther, 1992). Universal attempts during the last 15 yr to utilize these potent agonists 
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(because of their potential proprietary value) may have undermined scientific progress 
and commercialization of an existing technology. 
Only one serious attempt at using native GnRH in field trials was reported before 
our own laboratory embarked on the “rediscovery” of GnRH therapeutics in the 
anovulatory mare. The study was reported from New Zealand in the 1980’s that 
demonstrated subcutaneous infusion of native GnRH via osmotic minipumps at a rate of 
40 to 60 μg/h for 28 d during late spring transition (equivalent to April in North 
America) accelerated first ovulation by approximately 5 wk (Hyland & Jeffcott, 1988). 
Early work in our laboratory, using similar pumps, demonstrated that subcutaneous 
delivery of native GnRH at a very low rate (2.5 to 5 μg/h) can adequately stimulate 
secretion of LH to accelerate the onset of ovulatory cycles and breeding activity in 
persistently anovulatory mares after April 1 (Williams et al., 2007). However, chronic 
treatment of mares at these low doses, beginning in October and continuing through 
March, was unable to avert the development of seasonal anovulation, and did not 
accelerate spring transition (Collins et al., 2007). 
Subsequently, it was questioned whether there were differences in anterior 
pituitary responsiveness to GnRH before and after the winter solstice (Velez et al., 
2008). Velez et al. (2008) hypothesized that the adenohypophysis of the winter 
anovulatory mare is less responsive to GnRH stimulation at the time of the winter 
solstice (shortest day) compared to a period following two months of increasing 
photoperiod (mid- to late-February). Mares were treated subcutaneously with native 
GnRH using osmotic pumps at doses of 0, 20, or 100 μg/h. Results demonstrated that 
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anovulatory mares are actually less responsive to GnRH during the first 2 mo following 
the winter solstice than during the period just before or at the winter solstice. Mares 
responded to the 100 μg/h dose both before and after the winter solstice, but responded 
to the 20 μg/h dose only in December. Development of ovulatory follicles occurred 
during both periods in response to 100 μg/h, but follicle size did not change compared to 
controls in response to the 20-μg/h dose at either time period. Thus, it was concluded 
that the length of exposure to a non-permissive photoperiod has a greater negative 
impact on adenohypophyseal responsiveness to GnRH than absolute day-length (i.e., 
winter solstice) at the time of GnRH treatment. Most importantly, it appears that 
subcutaneous infusion of GnRH at a rate of 100 μg/h successfully induces synthesis and 
secretion of LH, resulting in development of preovulatory follicles (≥ 35 mm), and a 
greater proportion of spontaneous ovulations (7/10) at both times tested compared to 
controls and mares treated with 20 μg GnRH/h. However, two main managerial 
questions remain 1) what is the optimal time to begin treatment to hasten the spring 
reproductive transition to optimize subsequent foaling dates and 2) will mares treated 
with continuous native GnRH beginning prior to the spring reproductive transition 
maintain ovarian cyclicity and/or pregnancy following treatment removal? 
 
2.7 Challenging dogma 
If dogma is correct and GnRH is truly limiting in the winter anovulatory mare, 
then continuous administration of native GnRH (as opposed to agonists that are known 
to cause receptor down-regulation) might prevent the fall transition from an ovulatory to 
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anovulatory state in the mare. Using relatively small doses of native GnRH, Collins et al. 
(2007) continuously infused GnRH beginning before the fall transition (late 
September/early October) and failed to prevent winter anovulation or to hasten 
reproductive transition in the spring. Further, using the technique of intercavernous sinus 
(ICS) cannulation, Cooper et al. (2006) indicated that GnRH concentration, pulsatility, 
and amplitude do not vary across seasons in pituitary venous effluent illustrating that the 
reduction in secretion of LH occurring about the time of autumnal equinox may not be 
regulated through reduced secretion of GnRH. However, previous work involving the 
measurement of circulating concentration of GnRH indicates variation across seasons 
(Sharp & Grubaugh, 1987), while results pertaining to hypothalamic content (Strauss et 
al., 1979; Hart et al., 1984) are contradictory. Collectively, there has been an accrual of 
evidence indicating the possibility that decreased sensitivity of adenohypophyseal 
gonadotropes to GnRH may play a greater role in the development of winter anovulation 
than a decline in endogenous secretion of GnRH (Cooper et al., 2006; Collins et al., 
2007; Velez et al., 2008). Regardless of the nuances contributing to this theoretical 
debate, there is one simple and incontrovertibly clear fact: native GnRH can reverse 
seasonal anovulation in the mare if applied at the appropriate dose and for an adequate 
duration (Hyland & Jeffcott, 1988; Becker and Johnson, 1992; Velez et al., 2008). 
 
2.8 Inhibitory peptides as potential regulators of reproductive seasonality 
If one is to challenge currently accepted dogma regarding neuroendocrine control 
of reproductive seasonality in the equine, a suitable alternative must be postulated. This 
19 
 
would require a molecule capable of altering the responsiveness of the gonadotropes to 
GnRH, resulting in the 6 to 10-fold decline in LH and onset of the anovulatory season. 
This molecule would act by inhibiting signals that result in GnRH-stimulated LH 
release. The mechanisms could involve modulation of GnRH receptor function or 
intracellular signaling pathways. The presence of such a molecule and the nature of its 
signaling remains to be elucidated in the equine but may include a recently-discovered 
neuropeptide family, arginine phenylalanine-amide related peptide (RFRP). This family 
of neuropeptides are homologs of the avian peptide, gonadotropin-inhibiting hormone 
(GnIH). 
The first vertebrate in which GnIH was isolated was in Japanese quail and was 
aptly named for its ability to inhibit adenohypophyseal synthesis and secretion of LH in 
a dose-dependent manner in vitro and in vivo (Tsutsui et al., 2000; Ubuka et al., 2006). 
Both GnIH and RFRP have been linked to the regulation of reproductive seasonality in 
seasonal breeding species (rodents, avian, and ovine), with marked changes in 
GnIH/RFRP gene expression and peptide accumulation observed in the hypothalamus in 
response to changing photoperiod (Tsutsui et al., 2000; Ubuka et al., 2005; Clarke et al., 
2008; Revel et al., 2008). Moreover, RFRP directly suppresses secretion of LH and 
hypophyseal responsiveness to GnRH in those species (Tsutsui et al., 2000; Kriegsfeld el 
al., 2006). This family of peptides functions through the GnIH receptor that belongs to 
the G protein-coupled receptor superfamily. In the avian, GnIH receptor mRNA is 
expressed in the hypothalamus and pituitary (Yin et al., 2005). The mammalian homolog 
of the GnIH receptor is GPR147 (OT7T022, NPFF1; Fukusumi et al. 2006), expressed in 
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the hypothalamus and pituitary (rodents and humans; Hinuma et al. 2000; Ubuka et al., 
2009b). As a result of the location and function of this family of peptides and their 
receptor, an equine homolog of this peptide could play a role in reproductive seasonality 
in the equine by direct effects on the adenohypophysis. 
 
2.8.1 RFRP3 hypothalamic expression, distribution, and function 
Cellular GnIH/RFRP3 expression distribution and fiber projections are variable 
between species and these differences may lend clues to the function of the 
GnIH/RFRP3 system in the mare. In the avian, cell bodies are located within the 
paraventricular nucleus of the hypothalamus (PVN), with GnIH-immunoreactive fiber 
projections most prominently extending towards the median eminence (Bentley et al., 
2003; Ukena et al., 2003; Osugi et al., 2004), the site of GnRH exocytosis from neuronal 
terminals into the portal vasculature. Further, GnIH-containing fibers have been found in 
close proximity to GnRH neurons and fibers within the avian brain and GnRH-I and -II 
neurons express GnIH receptor (Bentley, 2003 2009). These observations indicate that 
GnIH may play both a central and peripheral role to regulate gonadotropin release in the 
avian. In the ovine, GnIH cell bodies are located within the dorsomedial nucleus of the 
hypothalamus (DMH) and PVN, with PVN cell bodies projecting towards the 
neurosecretory zone of the median eminence (Clarke et al., 2008). This supports the 
notion that RFRP3 acts directly at the level of the anterior pituitary to regulate 
gonadotropin release in the ovine (Clarke et al., 2008). In the equine, GnIH-
immunoreactive neurons have been localized to the DMH with GnIH-containing fibers 
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in close proximity to GnRH dendrites and cell bodies as well as projecting towards the 
median eminence (Amstalden, Bentley and Williams, unpublished observations). 
However, RFRP3 hypothalamic distribution has not been evaluated in the equine, nor 
have differences in RFRP3 expression levels been observed across seasons - two 
components essential in deducing where in the equine reproductive axis RFRP3 is 
regulated. 
 
2.8.2 Influence of melatonin on hypothalamic RFRP3 function 
One factor potentially regulating mammalian hypothalamic GnIH/RPRP3 
expression could be melatonin. Ubuka et al. (2005) demonstrated that GnIH-expressing 
cells also express the melatonin receptor (Mel1c) in the hypothalamus of avian species. 
Additionally, Gingerich et al. (2009) demonstrated a direct ability of melatonin infusion 
on immortalized hypothalamic cells to increase RFRP3 expression. Further, in the long-
day breeding hamster, chronic infusion (60 d) of melatonin during the breeding season 
inhibited RFRP3 expression to non-breeding season levels (Revel et al., 2008). 
Therefore, GnIH/RFRP3 could serve as the intermediary signal between melatonin 
secretion and GnRH synthesis and secretion. If this is the case, melatonin or 
norepinephrine (a potent stimulator of melatonin biosynthesis) infusion during the 
natural breeding season should increase hypothalamic RFRP3 expression in the mare. 
Alternatively, infusion of cannabinoids to attenuate norepinephrine-induced melatonin 
biosynthesis (Koch et al., 2006) during the non-breeding season may release the mare 
from seasonal anovulation.  
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2.8.3 RFRP3 hypophyseal expression and function 
The first vertebrate in which GnIH was isolated was Japanese quail and aptly 
named for its ability to inhibit adenohypophyseal synthesis and secretion of LH in a 
dose-dependent manner in vitro and in vivo (Tsutsui et al., 2000; Ubuka et al., 2006). 
Additional studies have illustrated a similar function of the mammalian homologue 
RFRP3 (Tsutsui et al., 2000; Kriegsfeld el al., 2006; Johnson et al., 2007; Clarke et al., 
2008; Anderson et al., 2009) that functions through G protein-coupled receptor 147 
(GPR147; alias NPFF1) expressed within the hypothalamus and pituitary (Hinuma et al. 
2000, Ubuka et al., 2009b). Work in the ovariectomized female rat and ewe, as well as in 
pituitary cell cultures, indicates that RFRP3 plays a functional role at the level of the 
hypophysis to reduce gonadotropin responsiveness (Clarke et al., 2008; Murakami et al., 
2008; Sari et al., 2009). This is further supported by evidence from anterograde tracing 
in the ewe that demonstrates RFRP3-immunoreactive cells project to the neurosecretory 
zone of the median eminence (Clarke et al., 2008). Further, reduced LHβ and FSHβ gene 
expression have been reported in GnRH-stimulated ovine pituitary cells treated with 
RFRP3 (Clarke et al., 2008). Interestingly, changes in FSHβ mRNA expression in 
pituitary cells collected from quail chronically treated with GnIH (Ubuka et al., 2006) 
and FSH levels in GnIH peripherally infused over 1 hr to ovariectomized ewes (Clarke 
et al., 2008) were not suppressed. Therefore, variation in GnIH/RFRP3 gonadotrope 
regulation exists between species and differences are dependent on treatment methods. 
Thus, it may prove fruitful to determine not only LHβ and FSHβ gene expression in 
equine gonadotropes treated both chronically and acutely with RFRP3, but also evaluate 
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differences in adenohypophyseal RFRP3 receptor (GPR147) gene expression across 
seasons to assess gonadotrope responsiveness as well as gonadotropin secretion in mares 
chronically infused with RFRP3. Alterations in one or more of these variables may be 
driving the seasonal reduction in ovarian activity that occurs during the non-breeding 
season in the mare. 
In addition to genomic studies, determining if RFRP3 has a functional role at the 
level of the hypophysis will facilitate in determining the site of action for this peptide. 
As a 6- to 10-fold reduction in circulating LH concentrations are observed during the 
non-breeding season of the mare and recent results (Cooper et al., 2006) indicate that 
GnRH is not limiting during this time, it is reasonable to deduce that RFRP3 may be 
suppressing the responsiveness of gonadotropes to GnRH. Others have reported 
suppressed secretion of LH in pituitary cell cultures of male quail (Ubuka et al., 2006), 
rat (Murakami et al., 2008), chicken (Ciccone et al., 2004), and sheep (Clarke et al., 
2008) treated with RFRP3. Interestingly, LH secretion was only suppressed in the 
presence of both GnIH/RFRP3 and GnRH. However, no reports have been published 
using equine pituitary cell culture to determine if RFRP3 infusion with or without GnRH 
suppresses LH secretion. 
 
2.8.4 Peripheral and central RFRP3 infusion 
Peripheral infusion of RFRP3 during the breeding and non-breeding seasons does 
indicate that that neither equine RFRP3 at any dose or manner tested, nor ovine RFRP3 
as a large single dose, is able to suppress episodic release or mean concentration of LH 
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in mares (Prezotto, 2012). Further, treatment with RFRP3 was ineffective in modifying 
GnRH-induced release of LH in the mare (Prezotto, 2012) using doses similar to that 
reported previously in studies where RFRP3 suppressed LH in ovariectomized ewes 
(Clarke et al., 2008) and castrated male calves (Kadokawa et al., 2009). Thus, these 
reports fail to support the hypothesis that RFRP3 acts as an inhibitory signal to suppress 
the secretion of LH through effects at the hypothalamic or hypophyseal level in the 
mare. Similar results have been reported in ovariectomized pre-pubertal gilts (Heidorn et 
al., 2010) and ovariectomized, estradiol-replaced rats (Anderson et al., 2009) treated 
with RFRP3 intracerebroventricularly. However, ovariectomized female rats treated 
intravenously with RFRP3 concomitantly with GnRH exhibited reduced peak 
concentrations of LH when compared to controls (Rizwan et al., 2009). Therefore, 
functional differences within the RFRP3 system exist between species and are dependent 
on the dose, route of administration, and steroidal environment. 
 
2.8.5 Role of RFRP3 during the breeding season 
In addition to seasonal changes in RFRP3, this peptide may also function during 
the estrous cycle of the breeding season. Recent work by Magee et al. (2009) indicates 
that a similar peptide, kisspeptin, plays a role in regulating spring transition in the mare 
via up-regulation of LH gonadotrope function. However, this alone does not account for 
the 6 to 10-fold decline in LH associated with the transition from the ovulatory to 
anovulatory season. Furthermore, kisspeptin also has increased hypothalamic mRNA 
and protein levels under the influence of estradiol in female rats (Kinoshita et al., 2005), 
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while the role of estradiol in GnIH/RFRP3 function remains debatable (Kriegsfeld et al., 
2006; Popa et al., 2008; Molnar et al., 2011). As the influence of estradiol in 
GnIH/RFRP3 function remains controversial, it is possible that the number of neurons 
expressing RFRP3 and cellular RFRP3 content in the hypothalamus of the mare could be 
elevated during the winter anovulatory period and luteal phase of the estrous cycle when 
photostimulation and circulating estradiol concentrations are minimized. Additionally, 
the role of the RFRP3 system in the mare could be gated down-stream of the mRNA 
level. Therefore, experiments designed to assess differences in RFRP3 translational rates 
as well as functional studies designed to evaluate vesicular exocytosis at neuronal 
terminals or receptor availability on target tissues may be necessary. 
 
2.8.6 GPR147 expression, distribution, and function 
Although RFRP3 appears to function through GPR147 expressed within both the 
hypothalamus and pituitary (Hinuma et al., 2000; Ubuka et al., 2009b), functional 
variability associated with RFRP3 effects has resulted in uncertainty regarding its 
mechanism of action in mammals. It is well documented that mammalian gonadotropes 
couple GnRH receptor with Gaq/11 to stimulate phospholipase C (PLC), resulting in the 
generation of inositol triphosphate (IP3) and diacylglycerol (DAG; Naor, 2009). These 
two components then activate protein kinase C (PKC) and trigger calcium mobilization 
to induce phosphorylation of mitogen-activated protein kinases (MAPKs; Naor, 2009). 
Mechanisms proposed in mammals to transmit GnIH/RFRP3 signal at the level of the 
gonadotrope ultimately result in inhibiting intracellular calcium mobilization (Clarke et 
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al., 2008), the primary GnRH receptor-induced signal for gonadotrope exocytosis 
(Stojilkovic and Catt, 1992; Stojilkovic and Catt, 1995), as well as phosphorylation of 
mitogen-activated protein kinases (ERK-1/2; Sari et al., 2009) to inhibit gonadotropin 
gene expression (Haisenleder et al., 1998). Therefore, GnIH/RFRP3 effectively reduces 
GnRH-induced gonadotropin synthesis and secretion. In the mare, data failed to 
demonstrate any functional effects of RFRP3 in vivo (Prezotto, 2012). However, 
recently, a selective antagonist for the NPFF1 receptor (RF9) has been shown to induce a 
potent release of LH in rats, mice, and sheep when administered centrally or peripherally 
(Pineda et al., 2010; Caraty et al., 2012; Rizwan et al., 2012), thus providing an 
additional approach for studying the RFRP3 system in the mare. The mechanism by 
which RF9 is functioning is unidentified. However, the possibility exists that the RFRP3 
system acts directly on GnRH neurons. To date, all reported species (avian, rodents, 
ovine, sub-primates, humans, and equine) exhibit GnIH/RFRP3-immunoreactive fibers 
in close proximity to GnRH neurons (Bentley et al., 2003; Kriegsfeld et al., 2006; Smith 
et al., 2008; Ubuka et al., 2008; Qi et al., 2009; Ubuka et al., 2009a; Ubuka et al., 2009b; 
Amstalden, Williams, and Bentley, unpublished observation). Furthermore, GPR147 is 
expressed in GnRH neurons in birds (Ubuka et al., 2008) and rodents (Rizwan et al., 
2012). Functional support for this hypothesis include the reduction in firing activity 
(Ducret et al., 2009; Ubuka et al., 2009b; Wu et al., 2009) and immediate early gene 
expression in GnRH neurons (Anderson et al., 2009) with administration of RFRP3. 
Furthermore, RFRP3/GnIH directly inhibits GnRH neurons by hyperpolarizing the 
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neuronal membrane through K+ conductance in dwarf gourami (Saito et al., 2010) 
allowing for the down-stream reduction in LH synthesis and secretion. 
 
2.9 Expected impact of this research 
The neuroendocrine control of reproductive seasonality is poorly characterized in 
the equine. Through investigations that address stimulatory and inhibitory mediators of 
the reproductive neuroendocrine axis of the mare, the equine industry will benefit at both 
a basic scientific and applied level. Using the information gathered from this research, 
the acceleration of reproductive transition from the winter anovulatory state and 
accelerated pregnancy may be possible using native GnRH. Additionally, experiments 
with RFRP3 may hold the key to an applied model to impede reproductive cyclicity in 
performance or feral horse populations or hasten reproductive cyclicity with the use of 
RFRP3 antagonists such as RF9. This expansion in the knowledge base of equine 
neuroendocrine function will be beneficial to our understanding of equine reproduction 
and to the equine industry.  
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CHAPTER III 
THERAPEUTIC APPLICATION OF NATIVE GNRH IN THE WINTER 
ANOVULATORY MARE, I: FREQUENCY OF REVERSION TO THE 
ANOVULATORY STATE FOLLOWING OVULATION INDUCTION AND  
CESSATION OF TREATMENT 
 
 
 
3.1 Synopsis 
The continuous administration of native GnRH to seasonally anovulatory mares 
stimulates successfully the synthesis and secretion of LH without pituitary refractoriness. 
Herein we tested the hypothesis that continuous administration of native GnRH, 
beginning in either early February or early March (North America), will rapidly 
stimulate follicular development and ovulation without resulting in reversion of cyclic 
mares to an anovulatory state following treatment withdrawal. Anovulatory mares 
received sham pumps (Control) or native GnRH (100 μg/h) for 28 d beginning either 
February 2 or 3 (GnRH-Feb) or March 2 or 3 (GnRH-Mar). Mean concentrations of LH 
were 5 to 7-fold greater in GnRH-Feb compared to control and GnRH-Mar mares 
through March 2 or 3. However, concentrations of LH returned to the winter baseline 
within 3 to 11 d after pump removal and all GnRH-Feb mares failed to remain cyclic 
following treatment withdrawal. Correspondingly, concentrations of LH in GnRH-Mar 
mares were greater (P < 0.001) than in control and GnRH-Feb mares for the 28-d period; 
however, ovulatory cycles continued in all mares after cessation of treatment. Follicular 
growth and frequency of spontaneous ovulation (6/10 GnRH-Feb; 9/10 GnRH-Mar, 1/11 
29 
 
controls, respectively) was greater (P < 0.01) in GnRH-treated mares. Continuous 
administration of native GnRH for 28 d, beginning in early February or March, elevated 
circulating LH adequately to stimulate follicular growth and spontaneous ovulation up to 
60 d earlier than in untreated controls. However, if continuous GnRH treatment is 
selected as the only therapeutic intervention, and mares are not pregnant, GnRH 
treatment must continue through March in order to ensure continued escape from the 
winter anovulatory state. 
 
3.2 Introduction 
The seasonal termination of ovarian cycles in mares, a process initiated near the 
time of the autumnal equinox and completed in most of the mare population by the 
winter solstice, is a significant managerial issue for professional horse breeders world-
wide (Ginther, 1992; Davies, 2003). Currently, the provision of supplemental lighting 
for at least 3 mo is the only practical intervention strategy available, and offers the 
ability to advance the operational breeding season by approximately 1 mo (Burkhart, 
1947; Ginther, 1992; Davies, 2003). 
From an endocrine perspective, one of the most conspicuous features associated 
with the winter anovulatory period in the mare is the marked decline in anterior pituitary 
synthesis and secretion of LH (Garcia and Ginther, 1975; Turner et al., 1979; Hart et al., 
1984). Johnson (1987) demonstrated unequivocally that hourly, very low-dose (2 µg) 
intravenous pulses of native GnRH could quickly increase circulating concentrations of 
LH, stimulate follicular growth, and initiate spontaneous ovulation in mares in a state of 
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deep winter anovulation. Importantly, a lesser but highly-effective pituitary response 
was noted with continuous administration of GnRH in a large-dose (100 µg/h; Becker 
and Johnson, 1992). These and other studies revealed that, unlike other female mammals 
(Belchetz et al., 1978; Knobil, 1981), an intermittent hypophysiotropic signal is not 
required for the equine GnRH receptor to remain functionally responsive (Johnson, 
1987; Hyland et al., 1987; Porter et al., 1997). Thus, unique opportunities for practical 
intervention strategies using GnRH seemed inevitable. 
Experiments with potent GnRH agonists (GnRHa), injected twice daily (Ginther 
and Bergfelt, 1990; Harrison et al., 1990; McCue et al., 1991; McCue et al., 1992) or 
administered as an implant or depot formulation soon followed (Harrison et al., 1990; 
Fitzgerald et al., 1993; Mumford et al., 1994). McCue et al. (1992) demonstrated 
efficacy of twice daily injections of GnRHa (buserelin) for achieving pregnancy with 
mares in a deep anovulatory state. Unfortunately, the more practical, continuous delivery 
of similar GnRHa resulted in low or inconsistent responses and evidence of pituitary 
desensitization (Harrison et al., 1990; Fitzgerald et al., 1993; Mumford et al., 1994). 
Hence, available evidence supports the practical superiority of continuously-applied, 
native GnRH, as opposed to GnRHa, for initiating follicular development and ovulation 
in mares in the middle of the non-breeding season (Hyland et al., 1987; Johnson, 1987; 
Becker and Johnson, 1992), and for accelerating the timing of pregnancy of mares in late 
transition (Hyland et al., 1987; Hyland and Jeffcott, 1988). Unfortunately, this paradigm 
has not been tested for its ability to accelerate the timing of pregnancy in mares in deep, 
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winter anovulation, nor is there a commercially-approved delivery platform available for 
this or related purposes. 
Our long-term objectives are to develop the physiological and managerial 
principals needed to apply GnRH therapeutics for routinely establishing pregnancies in 
the winter anovulatory mare. In the experiments described here, the primary interest was 
to determine whether anovulatory mares treated continuously for 28 d with native 
GnRH, beginning in either early February or early March (Northern Hemisphere), will 
establish normal luteal function following spontaneous ovulation and remain cyclic 
following treatment withdrawal. 
 
3.3 Materials and methods 
The Institutional Animal Care and Use Committee of Texas A&M University 
approved in advance all procedures used in this study. 
 
3.3.1 Animals and diets 
Thirty-one light horse mares, predominantly American Quarter Horses, were 
maintained on a pasture of mixed grasses and supplemented with coastal Bermuda grass 
hay and a pelleted concentrate (12% CP) as needed to maintain an average body 
condition score (BCS) of 5 (1 to 9 scale; Henneke et al., 1983). Mare BCS was assessed 
before treatment onset and monthly for the duration of the study. Mean BCS and age of 
the mares used in this study were 4.9 ± 0.3 and 9.3 ± 1.8, respectively. Mares had 
continual access to water and trace mineralized salt throughout the study.  
32 
 
3.3.2 Treatments and experimental design 
Beginning the first week of January and continuing for the next 3 wk, ovulatory 
status of mares was determined using transrectal ultrasonography (Honda HS-Feb500V, 
Honda Electronics Co., LTD) combined with serum concentrations of progesterone 
determined in jugular blood samples collected once weekly. Mares were confirmed as 
anovulatory based on the absence of a corpus luteum (CL), no follicle > 28 mm, and 
serum progesterone at baseline (~ 0.1 ng/mL) during this period. However, 6 of 31 
mares had follicles > 20 mm at the start of the experiment. Mares were stratified by age, 
starting BCS, and size of largest follicle and assigned randomly to 1 of 3 groups: 1) 
Control (n=11), 2) GnRH-Feb (n=10), or 3) GnRH-Mar (n=10). As the same mares were 
used as controls for GnRH-Feb and GnRH-Mar, one additional Control mare was 
included to account for potential spontaneous ovulation in this group. Thus, Control 
mares were classified as Control-Feb or Control-Mar during the 28-d treatment periods 
in February and March, respectively. When differences did not exist between Control-
Feb and Control-Mar, treatments were pooled for analysis. Treatments or sham 
treatments were initiated in each experimental group over 2 consecutive d on February 2 
or 3 and March 2 or 3. On February 2 or 3, mares assigned to GnRH-Feb were fitted 
surgically with subcutaneous Alzet osmotic pumps (model 2ML2; Durect Corp, 
Cupertino, CA) to deliver GnRH at a rate of 100 μg/h for 14 d. Control and GnRH-Mar 
mares were fitted similarly with sham pumps constructed of Silastic tubing (Dow 
Corning Corporation, Midland, MI) filled with medical grade silicone adhesive (Dow 
Corning Corporation, Midland, MI). On February 16 and 17, respectively, the initial 14-
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d pumps (GnRH-Feb) and sham pumps (control and GnRH-Mar) were removed and 
similar new pumps/sham pumps were installed. This same process was repeated in 
March except that GnRH-Mar mares received Alzet osmotic pumps, and control and 
GnRH-Feb mares received sham pumps. Figure 3.1 provides a time-line of the  
experiment. 
 
 
 
 
Fig. 3.1. Experimental time line depicting the treatments applied from January to May in 
control, GnRH-Feb, and GnRH-Mar treated mares. All mares were confirmed 
anovulatory utilizing transrectal ultrasonography and confirmation of serum 
concentrations of progesterone at baseline during the Pre-study period in January. 
Continuous, subcutaneous GnRH treatments were applied in either February or March. 
When not treated with GnRH, mares received sham pumps fitted subcutaneously 
followed by a Post-study period where blood was collected to monitor ovarian activity. 
 
 
 
3.3.3 Subcutaneous placement of pumps 
In accordance with manufacturer’s recommendations, Alzet pumps were 
incubated in physiological saline (0.9% NaCl solution) at 37ºC for 16 h prior to 
implantation. Mares were placed in a stock and sedated with detomidine hydrochloride 
(Dormosedan; 20-40 µg/kg BW; Pfizer Animal Health, New York, NY) if required. An 
area at the base of the neck (anterior to the scapula) was clipped and prepared for aseptic 
surgery using an iodophore (Purdue Product LP, Stamford, CT), povidone iodine 
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solution (Prepodyne, WestAgro, Kansas, MO), and 70% isopropanol. Three to five 
milliliters of a local anesthetic (lidocaine HCl, 2%; Agri Laboratories, St. Joseph, MO) 
was injected subcutaneously and a 2-cm incision was made through the skin with a 
sterile scalpel. A sterile, blunt instrument was used to expand the subcutaneous space 
making a pocket to accommodate the GnRH or sham pump. The incision was closed 
with non-absorbable synthetic sutures that were left in place for 7 d. At the end of each 
14-d period, Alzet pumps or sham pumps were removed and replaced using a similar 
procedure. Each consecutive 14-d device was applied at a different location by 
alternating between each side of the neck. Evacuated subcutaneous pockets were flushed 
with dilute povidone iodine solution followed by surgical closure with 2 to 3 synthetic 
sutures (Nylon, # 2). Implantation sites were monitored daily and, if inflammation or 
infection was observed, the skin over the surgical site was cleaned, disinfected with 
povidone iodine, and an antibacterial ointment applied. Only minor inflammatory 
changes were noted during this study. 
 
3.3.4 Estrous behavior 
Mares were teased daily in a large pen of 5 to 6 mares using an intact stallion in 
an adjacent pen separated by a solid panel. Teasing scores were assessed utilized a scale 
ranging from 1 to 4 (1, breaking down in the presence of the stallion; 2, winking in the 
presence of the stallion; 3, indifference to the stallion; 4, physical rejection evidenced by 
kicking, and ear-pinning). 
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3.3.5 Ultrasonography 
Transrectal ultrasonography was performed every 3 d beginning at onset of the 
study. When a follicle ≥ 30 mm was detected, ultrasound examinations were performed 
daily until ovulation was confirmed and continued for 30 d following cessation of each 
28-d treatment period. 
 
3.3.6 Blood collection 
Single blood samples were collected via jugular venipuncture at the following 
intervals: once weekly for four weeks (pre-trial), every other day for eight weeks (28-d 
treatment-period and 28-d follow up-period), and twice weekly for four weeks (post-
study) for determination of serum concentrations of progesterone and LH. Samples were 
placed on ice immediately for transport to the laboratory, kept under refrigeration at 4º C 
for approximately 1 h, and then allowed to clot at room temperature for approximately 
45 min prior to centrifugation. Samples were centrifuged at 4°C, with serum harvested 
and stored at -20°C until analysis. 
 
3.3.7 Hormone analyses 
Serum concentrations of LH were assayed in duplicate utilizing a double 
antibody RIA as validated previously in this laboratory (Williams et al., 2007). A highly 
purified equine LH (LH AFP-5130A) was used for both iodinated tracer and standards. 
An anti-equine LH antiserum (AFP-240580) was used at a dilution of 1:100,000. Serum 
concentrations of progesterone were assayed using a commercial kit (Diagnostic 
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Products Corporation, Los Angeles, CA) using a single-antibody coated tube RIA. Assay 
sensitivities were 0.1 ng/mL for both LH and progesterone. Inter- and intra-assay CV for 
the LH assay averaged 6.1 and 8.5%, respectively. Inter-and intra-assay CV for the 
progesterone assay averaged 4.2 and 7.2%, respectively. 
 
3.3.8 Statistical analysis 
Analysis of repeated measures was used to determine main effects of treatment 
on temporal changes in serum hormone concentration and estrous behavior utilizing a 
mixed model procedure (PROC MIXED) of the Statistical Analysis System (SAS). The 
model contained fixed effects for treatment, block, day, and the treatment x day 
interaction. The variable ‘day’ served as the repeated variable and ‘mare’ as the subject. 
Serum hormone concentrations and estrous behavior were also analyzed after 
normalization to onset of GnRH treatment (Feb 2 or 3 and March 2 or 3). The PROC 
GLM procedure of SAS was used to determine main effects of treatment on interval to 
ovulation, interval to declines in concentrations of LH post-ovulation and post-treatment 
withdrawal, interval from treatment withdrawal to baseline concentrations of LH, and 
change in follicle size during the 28-d treatment periods. The model contained fixed 
effects for treatment, and block. Comparisons were also made for mares that responded 
(ovulated) to GnRH treatments in February (n = 6) and March (n = 9). Enumerative data 
were analyzed using the FREQ procedure (PROC FREQ) of SAS and the Fisher’s Exact 
Test. Main effects were considered significant when P ≤ 0.05 and a trend toward 
37 
 
significance when P ≤ 0.10. Upon detection of a significant F-test, LS means were 
contrasted by the method of least significant difference. 
 
3.4 Results 
 
 
 
 
Fig. 3.2. Least squares mean concentrations of LH during February, March and April in 
which mares served as controls (n = 11) or were treated with GnRH (100 μg/h) 
continuously for 28 d beginning either on February 2 or 3 (GnRH-Feb; n= 10) or March 
2 or 3 (GnRH-Mar; n = 10). †Denotes a difference (P ≤ 0.02) between control and 
GnRH-Mar mares from GnRH-Feb mares. ‡Denotes a difference (P ≤ 0.02) between 
control and GnRH-Feb mares from GnRH-Mar mares. Treatment x day P < 0.0001. 
 
 
 
3.4.1 Serum LH 
Mean concentrations of LH did not differ among groups at the start of the 
experiment on February 2 and 3; however, within 48 h and throughout the remainder of 
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the 28-d treatment period, serum concentrations of LH were greater (P ≤ 0.02) for 
GnRH-Feb mares than in both Control-Feb and GnRH-Mar mares (Fig. 3.2). Removal of 
GnRH pumps in GnRH-Feb mares resulted in a decline in circulating LH, returning to 
pre-treatment values and not different from Control-Feb and GnRH-Mar-treated mares. 
Similarly, serum concentrations of LH in GnRH-Mar-treated mares increased rapidly 
within 48 h of treatment onset (March 2-3), with mean concentrations greater (P ≤ 0.02) 
than both Control-Mar and GnRH-Feb mares throughout the 28-d March treatment 
period (Fig. 3.2). When serum LH was normalized to the onset of GnRH or sham 
treatments in all groups (Fig. 3.3), mean concentrations of LH were greater (P ≤ 0.02) on 
treatment days 12 and18 in GnRH-Mar compared to GnRH-Feb mares. Following 
GnRH treatment withdrawal at the end of March, mean serum concentrations of LH 
dropped initially and then rebounded in association with a continuation of ovarian 
cyclicity in all GnRH-Mar mares that had spontaneously ovulated. During this same 
period (April), serum LH in control and GnRH-Feb mares was also increasing in concert  
with onset of the natural breeding season; thus, mean concentrations were similar among  
all groups at this time (Fig. 3.2). 
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Fig. 3.3. Least squares mean concentrations of LH, normalized to the day of onset of 
treatments, in which mares served as controls (n = 11) or were treated with GnRH (100 
μg/h) continuously for 28 d beginning either on February 2 or 3 (GnRH-Feb; n= 10) or 
March 2 or 3 (GnRH-Mar; n = 10). *Denote a difference (P ≤ 0.02) between GnRH-Feb 
and GnRH-Mar treated mares. †Denote a difference (P ≤ 0.02) between GnRH-treated 
and control mares. Treatment x day P < 0.0001. 
 
 
 
During both the February and March 28-d treatment periods, a biphasic pattern in 
mean serum concentrations of LH was observed. Initial mean peaks occurred on 
treatment days 10 and 12 in GnRH-Feb and GnRH-Mar-treated mares, followed by a 
second peak on treatment day 28 (Fig. 3.2). Individual mares exhibited declines in 
concentrations of LH from 0 to 10 d post-ovulation, with mean intervals (GnRH-Feb 3.3 
± 1.2 d; GnRH-Mar 3.8 ± 1.0 d) not different (P = 0.78) between GnRH treatments. 
Declines in circulating concentrations of LH also occurred between 3 and 8 d post-
treatment withdrawal, with mean intervals of 3.2 ± 0.3 d and 3.4 ± 0.3 d not different (P 
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= 0.66) for GnRH-Feb and GnRH-Mar, respectively. All GnRH-treated mares, excluding 
two GnRH-Mar mares, returned to baseline (0.1 ng/mL) concentrations of LH between 3 
and 11 d post-treatment withdrawal. However, interval from treatment withdrawal to 
baseline did not differ (P = 0.33) between GnRH-Feb (6.2 ± 0.7 d) and GnRH-Mar (7.3 
± 0.8 d). 
 
3.4.2 Ovarian morphology, ovulatory responses, and serum progesterone 
Mares treated with GnRH (GnRH-Feb and GnRH-Mar) had increased (P ≤ 0.01) 
follicular growth during the 28-d treatment period than controls (Table 3.1). The 
occurrence of spontaneous ovulation was greater (P ≤ 0.01) in GnRH treated mares 
compared to control mares with 6 of 10 GnRH-Feb and 9 of 10 GnRH-Mar treated 
mares ovulating spontaneously during their respective treatment periods compared to 
only 1 of 11 Control mares which ovulated during March (Fig. 3.4). Therefore, intervals 
to first ovulation for both GnRH-Feb and GnRH-Mar were decreased (P ≤ 0.001; Table 
3.2) relative to controls. For mares that ovulated during each of the respective treatment 
periods (GnRH-Feb: 6 of 10 and GnRH-Mar: 9 of 10), mean intervals to ovulation was 
14.0 ± 4.5 and 11.7 ± 3.7 d for GnRH-Feb and GnRH-Mar, respectively.  
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Table 3.1. Least squares mean (± SEM) maximal change in follicle size (mm) during the 
three 28-d treatment intervals. Mare treatments were control: sham pump surgically 
implanted subcutaneously for 28 d during February and March (n = 11); GnRH-Feb: 
GnRH delivered subcutaneously in saline at a rate of 100 μg/h for 28 d during February 
(two consecutive Alzet 2ML2; n = 10); and GnRH-Mar: GnRH delivered 
subcutaneously in saline at a rate of 100 μg/h for 28 d during March (two consecutive 
Alzet 2ML2; n = 10). a,bMeans without a common superscript letter differ (P ≤ 0.01) 
within treatment interval. 
 Treatment interval (d) 
Treatment 0 - 28 28 - 56 56 - 84 
Control 8.7 ± 2.0a 7.5 ± 2.5a 18.9 ± 3.2a 
GnRH-Feb 19.6 ± 2.1b 8.5 ± 2.6a - 
GnRH-Mar - 19.2 ± 2.6b 23.1 ± 3.4a 
 
 
 
 
Fig. 3.4. Proportion of mares that ovulated spontaneously within their respective 28-d 
treatment periods (GnRH-Feb and GnRH-Mar) compared to control mares during the 
same 28-d periods pooled. Proportions without a common superscript differ (P ≤ 0.01). 
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Table 3.2. Least squares mean (± SEM) interval (d) from onset of treatment to first 
ovulation normalized to onset of treatment. Mare treatments were control: sham pump 
surgically implanted subcutaneously for 28 d during February and March (n = 11); 
GnRH-Feb: GnRH delivered subcutaneously in saline at a rate of 100 μg/h for 28 d 
during February (two consecutive Alzet 2ML2; n = 10); and GnRH-Mar: GnRH 
delivered subcutaneously in saline at a rate of 100 μg/h for 28 d during March (two 
consecutive Alzet 2ML2; n = 10). a,b,cMeans without a common superscript letter differ 
(P ≤ 0.01) within parameter. 1Denotes the inclusion of all GnRH-treated mares (GnRH-
Feb n = 10; GnRH-Mar n = 10). 2Denotes the removal of GnRH-treated mares that failed 
to ovulate within the 28-d GnRH treatment period (GnRH-Feb n = 6; GnRH-Mar n = 9). 
 Interval to first ovulation (d) 
Treatment All1 Responsive2 
Control 75.8 ± 6.1a - 
GnRH-Feb 38.4 ± 6.4b 14.0 ± 4.5a 
GnRH-Mar 16.7 ± 6.4c 11.7 ± 3.7a 
 
 
 
All mares exhibited progesterone concentrations < 1 ng/mL for the 3-wk pre-trial 
period leading up to the experiment on February 2. Since blood samples were collected 
every other day during the experimental treatment periods and not relative to day of 
induced cycles, statistical contrasts of circulating progesterone are not relevant. 
However, all mares that ovulated during the 28 d treatment periods exhibited 
morphologically normal-appearing CL and typical patterns of progesterone secretion 
(Fig. 3.5). 
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Fig. 3.5. Least squares mean (± SEM) concentrations of progesterone during the 14-d 
period following ovulation in GnRH-Feb (n = 6) and GnRH-Mar (n = 9) mares. 
 
 
 
Mares treated with native GnRH in March and responsive to treatment 
(ovulated), continued to cycle following treatment withdrawal and exhibited two (n = 3) 
or three (n = 6) follicular waves by the end of May with corresponding increases in 
circulating concentrations of progesterone. Further, all mares that failed to ovulate 
within the 28-d treatment period (February n = 4; March n = 1) had elevated serum 
progesterone concentrations (peak progesterone ranging from 5.8 to 15.1 ng/mL) within 
60 days of treatment withdrawal and thus possess a functional hypothalamic-pituitary-
ovarian axis. 
 
3.4.3 Teasing scores 
Between days 3 to 16 and days 3 to 15 following initiation of treatments in 
GnRH-Feb and GnRH-Mar mares, respectively, the number of mares exhibiting estrus 
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was greater and thus mean teasing scores were lower (P ≤ 0.01) than in control mares 
(Fig. 3.6). GnRH-treated mares began exhibiting consecutive days of estrous behavior, 
equal to a teasing score of 1, between 3 and 16 d prior to ovulation. Mean duration of 
consecutive days of estrous behavior (teasing scores equal to 1) were 8.8 ± 1.5 d and 6.4 
± 1.2 d for GnRH-Feb and GnRH-Mar, respectively. However, duration of estrous 
behavior was not different (P = 0.23) between GnRH treatments and all GnRH-treated  
mares demonstrated estrous behavior on the day of ovulation. 
 
 
 
 
Fig. 3.6. Least squares mean teasing scores in control, GnRH-Feb, and GnRH-Mar 
groups. Individual scores (1 = mare breaking-down in the presence of the stallion to 4 = 
mare rejecting the stallion) were assigned daily. †Denotes a difference (P ≤ 0.01) 
between GnRH-Feb treated mares and control. ‡Denotes a difference (P ≤ 0.01) between 
GnRH-Mar treated mares and controls. Treatment x day; P < 0.0001.  
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3.5 Discussion 
Results of the current study confirm that continuous treatment with native GnRH 
is an effective means of initiating ovulatory cycles beginning as early as 2 mo before the 
average onset of the natural breeding season (Johnson, 1987; Becker & Johnson, 1992). 
However, under the conditions of this study, in which ovulations were allowed to occur 
spontaneously, it appears that mares will not continue to exhibit estrous cycles following 
termination of treatment on March 2 or 3. To the contrary, when treatments are initiated 
on March 2 or 3 and terminated in late March, ovulatory cycles continue. The basis of 
this observation is likely the lack of adequate endogenous secretion of GnRH in 
February and its subsequent increase as mares transition into the natural breeding season 
in late March (Sharp and Grubaugh, 1987). Thus, regardless of whether treatment is 
initiated in February or March, it appears that it must be continued to the end of March if 
applied as in the current experiment. However, based on two other published studies, it 
is possible that continuous treatment through March may not be required if the 
preovulatory follicle is induced to ovulate using an exogenous gonadotropin or a 
gonadotropin surge-inducing treatment. In one study (Bergfelt and Ginther, 1992), mares 
with minimal ovarian activity at initiation of GnRH treatment were shown to be more 
likely to develop subnormal luteal function following spontaneous ovulation. In contrast, 
McCue et al (1992), using twice daily injections of buserelin to stimulate follicular 
development in mares in deep winter anovulation, observed high pregnancy rates (> 
70%) and low (7%) embryonic losses when preovulatory follicles were induced to 
ovulate using hCG. Therefore, subnormal luteal function, increased risk of embryonic 
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loss, and failure to continue to ovulate (non-pregnant mares) may potentially be avoided 
after termination of continuous GnRH treatment if the first ovulation is induced using 
hCG or an ovulatory dose of a surge-inducing treatment with GnRH or GnRHa. 
In association with the above observations, and as expected, there was a steady 
increase in circulating LH in response to GnRH treatments in both months. Mares 
treated with GnRH at a rate of 100 µg/h for 28 d exhibited a 5 to 7-fold increase in 
circulating LH within 2 wk, further substantiating the well-established thesis that 
continuous infusion of native GnRH in the mare does not cause overt GnRH receptor 
down-regulation as it does in other species (Belchetz et al., 1978; Porter et al., 1997). In 
addition, the mean treatment response to continuous GnRH treatment was biphasic. 
Peaks in mean concentrations of LH were observed on treatment days 10 and 12 and 
again on day 28 for both GnRH-Feb and GnRH-Mar groups. Upon evaluation of 
concentrations of LH for individual mares, the initial peak appears to be associated with 
the occurrence of falling concentrations of LH post-ovulation in a majority of the mares 
during each treatment month. The progressive decline in circulating concentrations of 
LH occurring 2 to 7 d post-ovulation is well documented during the natural breeding 
season (Evans and Irvine, 1975; Geschwind et al., 1975; Noden et al., 1975; Pattison et 
al., 1975) and appear to be consistent with observations in the current study. The 
descending aspect of the second peak was likely a function of treatment withdrawal in 
each group. A similar pattern of response to continuous GnRH treatments in the mare 
was reported by Hyland et al. (1987). However, in that study, peaks were observed on 
days 7 and 21 with intervals to first ovulation averaging 19.9 ± 1.7 d. Therefore, 
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ovulation was associated with the second peak in circulating LH in that study. This 
differential response may potentially be accounted for by the greater dose of GnRH 
given in the current study (100 µg/h) compared to the previous work (~ 40-60 µg/h). In 
addition, the minimum peak concentration of LH sufficient to induce ovulation during 
February was 0.7 ng/mL in responsive mares; however, non-responsive mares also 
exhibited peak concentrations of LH between 0.8 and 1.8 ng/mL. Thus, the minimum 
threshold concentration of LH needed to develop a spontaneously-ovulatory follicle in 
the winter anovulatory mare appears to vary. As noted below, this did not appear to be 
related to the size of the largest follicle at the onset of treatment in the current 
experiment. 
The GnRH treatments used in the current work induced follicular growth and 
markedly accelerated timing of first spontaneous ovulation in 15 of 20 (75%) treated 
mares during February or March, compared to only 1 of 11control mares during the 
same interval. These ovulatory responses were similar to those reported by others using 
both native GnRH (Johnson, 1987; Hyland and Jeffcott, 1988; Becker and Johnson, 
1992; Thorson et al., 2011) and GnRH agonists (Bergfelt and Ginther, 1992; McCue et 
al., 1992; Fitzgerald et al., 1993; Mumford et al., 1994), and intervals to first ovulation 
were comparable to that reported previously (Allen et al., 1987; Hyland et al., 1987; 
Hyland and Jeffcott, 1988; McCue et al., 1992). However, this is the first study to show 
that winter anovulatory mares, if treated only in February (North America), do not 
continue to exhibit ovarian cycles following treatment withdrawal when allowed to 
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ovulate spontaneously. In contrast, if mares were treated through March, ovarian 
cyclicity persisted. 
Ovarian responsiveness of mares to GnRH treatment did not appear to differ 
appreciably between mares having follicles lesser or greater than 20 mm in diameter, 
and agree with an accompanying study (Thorson et al., 2011). Other reports have 
indicated that size of the largest follicle at treatment onset does have a major influence 
on timing and frequency of ovarian responses (Ginther and Bergfelt, 1990; Bergfelt and 
Ginther, 1992). This may be related directly to the concentrations of LH achieved in the 
peripheral circulation in response to various treatments, some of which have been much 
less effective than that described here and in other reports (Johnson, 1987; Becker and 
Johnson, 1992). In spite of the relatively high concentrations of LH induced by GnRH-
treatments in the winter anovulatory mare, multiple ovulations were not observed in 
GnRH-treated mares in our study. However, multiple ovulations has been reported in 
response to potent GnRHa by others during the winter anovulatory season (McCue et al., 
1992), spring transition (Ginther and Bergfelt, 1990; Raz et al., 2009), and breeding 
season (Fitzgerald et al., 1993). Treatment with native hormone has also been shown to 
increase the rate of multiple ovulation during the anovulatory season but only when 
delivered intravenously in a continuous or pulsatile manner (Johnson and Becker, 1988; 
Becker and Johnson, 1992) and not when administered subcutaneously (Velez et al., 
2008; Thorson et al., 2011). The basis of these differing results is not clear. Interestingly, 
Ginther and Bergfelt (1990) reported a greater frequency of multiple ovulations (64%) 
when the largest follicle present at the time of treatment onset was larger than 25 mm, 
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whereas Raz et al. (2009) observed only a 7% incidence of multiple ovulations when 
GnRH treatment was initiated in mares bearing follicles greater than 25mm. Breed type 
appears also to play a significant role in the rate of multiple ovulations, with Quarter 
Horse mares exhibiting a less frequent incidence than Thoroughbred mares (Ginther, 
1982). In the current work, the majority of mares were Quarter Horse or grade mares. 
Duration of estrus behavior ranges from 2 to 12 d for individual mares, with 
mean days in estrus during February (6.7 d) and March (8.4 d) greater than that observed 
during the natural breeding season (April-October, 5.2 d; Hughes et al., 1972; Ginther, 
1992). Varying degrees of teasing behavior in this study increased markedly soon after 
the onset of GnRH treatments in both February and March-treated mares, occurring well 
in advance of the presence of a large follicle. This phenomenon has been observed 
before (Thorson et al., 2011) and may be a function of heightened sensitivity to ovarian 
steroids (estradiol, androgens) during the anovulatory period. 
Johnson and Becker (1988) reported measurable levels of estradiol within 3 to 7 
d of beginning pulsatile GnRH infusion in the winter anovulatory mare, observing mean 
peak concentrations of estradiol (20 ± 2 pg/mL) similar to peak concentrations observed 
during the breeding season (20 ± 3 pg/mL; Daels et al., 1991). Furthermore, 
concentrations of estradiol in mares treated with GnRH in a pulsatile fashion were 
greater than mean peak concentrations observed during the winter anovulatory (1.3 ± 0.3 
pg/mL), transitional (2.0 ± 0.5 pg/mL), and preovulatory period of the first vernal 
transition ovulation (6.3 ± 0.7 pg/mL) of non-GnRH-treated mares (Donadeu and 
Ginther, 2002). In contrast, Hyland et al (1987) reported that despite the occurrence of 
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normal ovulations and formation of normal CL, estradiol concentrations remained 
undetectable throughout a 28-d continuous GnRH treatment period. Another possibility 
for precocious estrus behavior is heightened androgen production by small follicles, but 
this is purely speculative and has not been tested. Further, all mares in the current 
experiment that developed a large follicle and ovulated in response to GnRH treatment 
exhibited full expression of estrous behavior, equivalent to a teasing score of 1, during 
the periovulatory period. This finding is indicative of steroidogenically-competent 
ovarian follicles that are potentially fertile as reported elsewhere (Bergfelt & Ginther, 
1992; McCue et al., 1992; Thorson et al., 2011). 
In conclusion, the current study indicates that the robustness of anterior pituitary 
and ovarian responses of winter anovulatory mares to continuous GnRH treatments are 
similar whether initiated in early February or March in North America. However, since 
strategies to accelerate Julian day foaling dates are the primary concern of breeders, it 
would seem plausible to begin such treatments in early February rather than in March. If 
this approach is chosen and mares are allowed to ovulate spontaneously, without any 
additional gonadotropic support, it appears that continuous GnRH therapy would need to 
continue to the end of March in order to assure continued cyclicity in the absence of 
pregnancy. However, prevailing evidence indicates that continued treatment following 
ovulation may not be necessary (McCue et al., 1992) if mares are induced to ovulate 
with additional gonadotropic support (e.g., hCG or surge-inducing treatment with 
GnRHa). Such a strategy would help to ensure normal luteal function and thus 
maintenance of pregnancy if mares are bred. In an accompanying study (Thorson et al., 
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2011), continuous GnRH treatment through March was used successfully in conjunction 
with hCG-induced ovulation. However, more direct tests are needed to determine 
whether continuous GnRH treatment can be terminated in a normal management 
scenario if ovulations are induced as described above as opposed to being allowed to 
occur spontaneously. Nonetheless, in spite of the biological advantage of native GnRH 
in this setting, as shown in the current and accompanying report (Thorson et al., 2011), 
its value continues to remain unexploited from a commercial perspective. This appears 
to be driven mainly by the current lack of a practical and efficient delivery platform that 
does not require minor surgery (e.g., injectable depot delivery). This laboratory is in the 
process of investigating the development of such an approach.  
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CHAPTER IV 
THERAPEUTIC APPLICATION OF NATIVE GNRH IN THE WINTER 
ANOVULATORY MARE, II: ACCELERATING THE TIMING OF  
PREGNANCY 
 
 
 
4.1 Synopsis 
Onset of the winter anovulatory period in mares is associated with a marked 
diminution in adenohypophyseal synthesis and release of LH. Native GnRH, unlike its 
synthetic agonists, stimulates the synthesis and secretion of LH in mares without 
pituitary refractoriness. Herein we tested the hypotheses that 1) the average Julian day of 
pregnancy can be accelerated by up to 2 mo in winter anovulatory mares treated 
continuously with native GnRH beginning on February 1 and 2) mares will sustain luteal 
function and pregnancy following treatment withdrawal. Forty-two winter anovulatory 
mares were stratified by age, BCS, and size of largest follicle across two locations in a 
randomized design and assigned to 1 of 3 groups (n = 14/group): 1) Control: untreated; 
2) GnRH-14: GnRH delivered subcutaneously in saline at a rate of 100 μg/h for 8 wk 
(Feb. 1–Mar. 29) using 4 consecutive 14-d pumps (Alzet 2ML2), or 3) GnRH-28: GnRH 
delivered as in 2, but using two, 28-d pumps (Alzet 2ML4). Upon development of a 35 
mm follicle and expression of estrus, mares were bred the following day and treated with 
hCG. Pregnancies were confirmed by transrectal ultrasonography on days 14, 24, 33, 
and 45, with blood samples collected to assess luteal function. Mares treated with GnRH 
(GnRH-14 and GnRH-28) exhibited marked increases (P ≤ 0.003) in the frequency of 
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development of a 35 mm follicle, submission rate for live cover/AI, ovulation, and 
pregnancy compared to Control mares on treatment day 56 (March 29). Interval to first 
35 mm follicle was 51.8 ± 4.9, 15.1 ± 4.9, and 23.5 ± 4.9 d (LSmean ± SEM) for 
Control, GnRH-14 and GnRH-28, respectively. Interval to pregnancy was 65.3 ± 6.8, 
27.9 ± 7.1, and 29.2 ± 6.8 d (LSmean ± SEM) for Control, GnRH-14 and GnRH-28, 
respectively,excluding one GnRH-14 mares that failed become pregnant over four 
cycles. By the end of the treatment period (Mar. 29), only 21% of Control mares were 
pregnant compared to 79% of GnRH treated mares. Further, mean serum concentrations 
of progesterone were similar to (GnRH-28; P = 0.26) or greater than (GnRH-14; P = 
0.01) that of Control mares from day 0 to 46 post-breeding. These data illustrate that 
continuous administration of native GnRH is a practical and highly efficient option for 
managing seasonal anovulation in mares. 
 
4.2 Introduction 
Approximately 85% of mares transition into an anovulatory state during the early 
to late fall (September-December) and remain anovulatory for variable periods until after 
the spring equinox (Ginther, 1992). However, a majority of breed registries utilize the 
universal birth dates of January 1 and July 1 for foals born in the northern and southern 
hemispheres, respectively (Ginther, 1992; Davies-Morel, 2003). Thus, foals born as near 
to those dates as possible within respective locations have a competitive edge during the 
first 2 yr of competition because of their greater maturity. This has forced breeders to 
adopt an operational breeding season that begins well before the natural resumption of 
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ovarian cycles. Currently, the provision of supplemental lighting for approximately 3 
mo, beginning before the winter equinox, is the only practical intervention strategy 
available for advancing the operational breeding season (Ginther, 1992; Davies-Morel, 
2003). 
As summarized in a recent review (Williams et al., 2012), continuously-applied, 
native GnRH (as opposed to GnRH agonists) has been shown to provide an efficacious 
pharmacological strategy for initiating follicular development and ovulation in mares in 
deep winter anovulation (Johnson, 1987; Becker and Johnson, 1992; Hyland et al., 
1987), and for accelerating the timing of pregnancy of mares in late transition (Hyland et 
al., 1987; Hyland and Jeffcott, 1988). However, this approach has not been tested for its 
ability to routinely accelerate the timing of pregnancy in anovulatory mares several 
months before natural reproductive transition. Moreover, there are no commercially-
available formulations for delivering native GnRH to achieve this end. Thus, our long-
term objectives are to develop managerial principles using native GnRH that 
successfully addresses these limitations. 
In studies reported in an accompanying manuscript, 28-d continuous GnRH 
treatment, begun in either early February or early March, rapidly increased follicular 
growth and frequency of ovulation in anovulatory mares. However, mares in which 
cycles were induced in February (North American) failed to continue to cycle in March. 
McCue (1992) demonstrated that deeply anestrous mares (February) that were 
stimulated to develop ovulatory follicles using twice daily injections of buserelin, and 
induced to ovulate with hCG, exhibited normal luteal function and maintained 
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pregnancies at a normal rate (< 10% pregnancy loss). Taken together, the foregoing 
indicate that ovarian cyclicity, CL function, and pregnancy maintenance will be normal 
if, following development of a large follicle, ovulation is induced with hCG or other 
gonadotropin surge-inducing methodology. Herein, we tested the hypothesis that 
continuous native GnRH therapy, in combination with hCG-induced ovulation, would 
advance the timing of pregnancy by up to 2 mo in winter anovulatory mares beginning in 
early February (North America). 
 
4.3 Materials and methods 
The Institutional Animal Care and Use Committee of Texas A&M University 
approved in advance all procedures used in this study. 
 
4.3.1 Animals and diets 
A total of 42 standard horse mares (Quarter Horse and grade) were utilized at 
two locations: Animal Reproduction Laboratory, Texas A&M AgriLife Research 
Station, Beeville (Location 1), and Texas A&M University Horse Center, Texas A&M 
University, College Station (Location 2). Mares were stratified by age, body condition 
score (BCS), and size of largest follicle across the two locations in a randomized design. 
Mares (21 per location) were maintained on pasture and supplemented with a coastal hay 
and a pelleted concentrate (Crossroad All-Stock CRS Sweet 12) as needed to maintain 
an average BCS of 5 (1 to 9 scale; Henneke et al., 1983). Mares had continual access to 
water and trace mineralized salt throughout the study. 
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4.3.2 Experimental design and treatment allocation 
In January, 3 wk before the start of the study, mares were examined once weekly 
using transrectal ultrasonography (Honda HS-Feb500V, Honda Electronics Co., LTD) to 
confirm establishment of the winter anovulatory state. In addition, pre-study jugular 
blood samples were collected once weekly for determination of progesterone 
concentrations as an adjunct to ultrasonography for assessing ovarian status. Only mares 
without an ultrasonically-definable CL, serum progesterone ≤ 1 ng/mL, and no follicle > 
29 mm during this 3-wk period were used on the study. However, 7 of 42 mares had 
follicles > 20 mm at the start of the experiment. Mares were stratified by age, BCS, and 
size of largest follicle and assigned randomly to 1 of 3 groups (n = 14/group): 1) 
Control; untreated controls, 2) GnRH-14 (GnRH delivered subcutaneously in saline at a 
rate of 100 µg/h for 56 d with pumps changed at 14-d intervals (Feb. 1 – Mar. 29), or 3) 
GnRH-28 (GnRH treatment delivered as in 2 for 56 d, with pumps changed at 28 d 
intervals). Groups 2 and 3 were applied using four 2ML2 (GnRH-14) or two 2ML4 
(GnRH-28) Alzet osmotic pumps (Durect Corporation, Cupertino, CA), respectively. 
Each pump had a volume of 2 ± 0.2 mL, and delivered a solution of GnRH (20 or 40 
mg/mL) in saline at a rate of 5.0 (2ML2) or 2.5 µL/h (2ML4) for 14 (GnRH-14) or 28 
(GnRH-28) d, respectively. For GnRH-14 and GnRH-28, each consecutive pump was 
inserted at the end of the functional term of the previous pump. The basis of the GnRH-
14 vs GnRH-28 osmotic pump comparison in this study was to ascertain whether 
functional differences could be detected between those placed subcutaneously over a 28 
vs 14-d period in mares maintained in a natural outdoor environment. 
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4.3.3 Osmotic pump insertion 
Mares were placed in a stock and sedated with detomidine HCl (Dormosedan, 
Pfizer Animal Health, New York, NY) at a rate of 20 to 40 µg/kg BW, if required. An 
area at the base of the neck (anterior to the scapula) was clipped, scrubbed with an 
iodophore, and disinfected with povidone iodine solution and 70% isopropanol. Three to 
five milliliters of 2% lidocaine HCl (Agri Laboratories, St. Joseph, MO) was injected 
subcutaneously and a 2- to 3-cm incision made through the skin with a sterile scalpel. A 
sterile, blunt instrument was used to expand the subcutaneous space making a pocket to 
accommodate the GnRH pump. The incision was closed with non-absorbable synthetic 
suture that was left in place for 7 d and an equine approved dressing applied to the site of 
incision. After 14 or 28 d, spent GnRH pumps were removed and replaced with a 
functional GnRH pump at another location at the base of the neck on the contralateral 
side as described above. Evacuated subcutaneous pockets were flushed with dilute 
povidone iodine solution followed by surgical closure with non-absorbable synthetic 
suture. All GnRH pumps were surgically removed at the end of the study. Mares 
observed with inflamed or infected skin were cleaned daily, disinfected with povidone 
iodine, and an antibacterial ointment was applied. This occurred only rarely.  
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4.3.4 Teasing score 
Mares were teased daily in a large pen of 5 to 6 mares using an intact stallion in 
an adjacent pen separated by a solid panel. Teasing scores were assessed on a scale of 1 
to 4 (1, mare breaks down in the presence of the stallion; 2, vulvar winking in the 
presence of the stallion; 3, indifference to the stallion’s presence; 4, rejects stallion). 
Only mares with a teasing score of 1 were bred. 
 
4.3.5 Ultrasonography 
Transrectal ultrasonography (Honda HS-Feb500V, Honda Electronics Co., LTD; 
Aloka SSD-900V, Aloka, Inc.) was performed every 3 d until a follicle measuring ≥ 30 
mm was detected. Once a follicle measuring 30 mm was observed, ultrasonography was 
performed daily to confirm time of ovulation following natural service or AI and 
treatment with hCG (see description below). Beginning 14 d after the day of confirmed 
ovulation, mares were examined for the presence of an embryonic vesicle. Detected 
pregnancies were confirmed on days 24, 33, and 45 on the basis of embryonic 
development and presence of a fetal heartbeat. Mares found to be non-pregnant were 
returned to the previous ultrasonography schedule for non-pregnant mares until 
confirmation of pregnancy or through 4 estrous cycles if not pregnant. 
 
4.3.6 Natural service and artificial insemination 
When a follicle ≥ 35mm was first observed ultrasonographically and estrus 
detected, mares were either bred on the following day (~ 24 h) by natural service using 1 
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of 2 fertile, experienced stallions (Location 1) or were bred by AI using extended cooled 
semen collected from 1 of 2 stallions with known fertility (Location 2). Immediately 
following natural service/AI, each mare received 2000 IU hCG (2 mL im, Chorulon; 
Intervet Inc., Millsboro, DE) to induce ovulation. Stallions used at each location for 
natural service or semen collection underwent a standard breeding soundness 
examination. The majority (> 90%) of mares at each location were bred/inseminated 
using a single predominant stallion at each location. A few mares at each location were 
booked to other stallions and were bred/inseminated using the alternate stallions. 
Artificial insemination breeding doses contained at least 500 million progressively 
motile sperm cells in a standard extender (E-Z Mixin CST, Animal Reproduction 
Systems, Chino, CA). Dismount samples were collected for each live cover breeding for 
assessment of sperm cell number and motility. Natural service and artificial insemination 
were continued through June. 
 
4.3.7 Blood collection 
Single blood samples (10 mL) were collected via jugular venipuncture into sterile 
blood collection tubes with no additives (Tyco Healthcare Group LP, Mansfield, MA). 
Samples were collected once weekly during the pre-treatment period, then every other 
day beginning on the first day of breeding/insemination until 46 d post-breeding for 
determination of serum concentrations of progesterone. Samples were placed on ice or 
under refrigeration (4° C) for approximately 1 h and then allowed to clot at room 
temperature for approximately 45 min prior to centrifugation. Samples were centrifuged 
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for 45 min at 4°C, and serum harvested and stored at -20˚C until determination of 
progesterone by RIA. 
 
4.3.8 Hormone analyses 
Serum concentrations of progesterone were determined using a commercial RIA 
kit assay (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA) as 
reported previously from this laboratory (Williams et al., 2007). The interassay CV of 
the low and high references averaged 3.7 and 4.2%, while the intraassay CV was 7.4%. 
 
4.3.9 Statistical analysis 
Frequency data (presence of a follicle ≥ 35 mm, breeding, ovulation, and 
pregnancy) were analyzed using the CATMOD procedure of the Statistical Analysis 
System (SAS Inst. Inc., Cary, NC) in order to account for location effects in the model 
and the Fisher’s Exact Test of PROC FREQ. Analysis of repeated measures was used to 
determine main effects of treatment on serum concentrations of progesterone utilizing 
the PROC MIXED procedure of SAS. Fixed effects were treatment, location, day, and 
treatment x day interaction. The variable ‘day’ served as the repeated variable and 
‘mare’ as the subject. The PROC GLM procedure of SAS was used to determine main 
effects of treatment on reproductive event intervals. Sources of variation were treatment, 
location, and treatment by location interaction. The LS Means statement was used to 
compare means when significant differences were detected using PROC MIXED and 
PROC GLM, respectively. Pearson correlation coefficients were determined using 
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PROC CORR, while linear regression analysis was performed using PROC REG to 
relate initial follicle size to interval to first breeding. Main effects were considered 
significant when P ≤ 0.05 and a trend toward significance when P ≤ 0.10. 
 
4.4 Results 
4.4.1 Reproductive end-points 
Location had no effect (P ≥ 0.48) on any of the reproductive end-points assessed. 
No differences (P ≥ 0.48) were observed between GnRH-14 and GnRH-28; thus, the 
treatment groups were pooled for comparisons of reproductive end-points to controls. 
Mares treated with GnRH had a markedly increased frequency of development of a 35 
mm follicle (P = 0.003), submission rate for live cover/AI (P = 0.003), ovulation (P = 
0.0002), and pregnancy (P = 0.0004; Fig. 4.1) compared to Control mares by the end of 
the treatment period (March 29). By the end of the treatment period (March 29), only 
21.4% of Control mares were pregnant compared to 78.6% of GnRH treated mares. 
Mean intervals to each reproductive end-point are summarized in Table 4.1 and 
demonstrate clearly the large effects of continuous GnRH treatment on reproductive 
variables compared to controls.  
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Fig. 4.1. Cumulative incidence of reproductive events of first: 35 mm follicle, breeding, 
ovulation, and pregnancy for GnRH therapeutics trial during the 56 day treatment 
period. Treatments were control: untreated (n = 14); GnRH-14: GnRH delivered 
subcutaneously in saline at a rate of 100 μg/h for 8 wk (Feb. 1 – Mar. 29) using four 
consecutive 14-d pumps (Alzet 2ML2; n = 14), and GnRH-28: GnRH delivered as in 
GnRH-14, but using two, 28-d pumps (Alzet 2ML4; n = 14). GnRH treatments did not 
differ (P ≥ 0.48) and therefore data are pooled in this figure (n = 28). Asterisks denote 
significant differences (P ≤ 0.03) between treatments within reproductive events. 
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Table 4.1. Least squares means (± SEM) interval to first 35 mm follicle, breeding, 
ovulation, and pregnancy for mares in GnRH therapeutics trial. Mare treatments were 
control: untreated (n = 14), GnRH-14: GnRH delivered subcutaneously in saline at a rate 
of 100 μg/h for 8 wk (Feb. 1 – Mar. 29) using four consecutive 14-d pumps (Alzet 
2ML2; n = 14, n = 14, n = 14, and n = 13 for 35 mm follicle, ovulation, breeding, and 
pregnancy, respectively), and GnRH-28: GnRH delivered as in GnRH-14, but using two, 
28-d pumps (Alzet 2ML4; n = 14). a,b,cMeans without a common superscript letter differ 
(P ≤ .0006) within reproductive events. 
 Treatment 
Intervals to first, days: 
Control GnRH-14 GnRH-28 
     35 mm follicle 51.8 ± 4.9a 15.1 ± 4.9b 23.5 ± 4.9b 
     Breeding 52.1 ± 4.9a 15.5 ± 4.9b 23.8 ± 4.9b 
     Ovulation 55.6 ± 4.9a 17.4 ± 4.9b 26.2 ± 4.9b 
     Pregnancy 65.3 ± 6.8a 27.9 ± 7.1b 29.2 ± 6.8b 
 
 
 
4.4.2 Serum concentrations of progesterone 
Location tended to influence serum concentrations of progesterone with mares in 
College Station (11.0 ± 1.2 ng/mL) tending to have increased (P ≥ 0.09) serum 
concentrations of progesterone compared to mares in Beeville (8.0 ±1.3 ng/mL). No 
treatment by day interaction (P = 0.17) was observed for serum concentrations of 
progesterone during induced (GnRH-treated) and naturally-occurring (Control) luteal 
phases; however, mean serum concentrations of progesterone tended to be greater (P = 
0.06) in GnRH-14 (12.7 ± 1.6 ng/mL) than GnRH-28 (9.3 ± 1.6 ng/mL) and greater (P = 
0.0006) in GnRH-14 than in Control mares (6.7 ± 1.5 ng/mL) that ovulated during the 
entire experiment. As expected, serum concentrations of progesterone increased (P < 
0.0001) as pregnancy progressed (Fig. 4.2). 
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Fig. 4.2. Serum concentration of progesterone (LS Means + SEM) from day 0 to 46 
post-breeding for mares in GnRH therapeutics trial. Mare treatments were control: 
untreated (n = 14, 14, 14, 14, and 13 for days 0, 14, 24, 34, and 46, respectively), GnRH-
14: GnRH delivered subcutaneously in saline at a rate of 100 μg/h for 8 wk (Feb. 1 – 
Mar. 29) using four consecutive 14-d pumps (Alzet 2ML2; n = 14, 14, 12, 12, and 12 for 
days 0, 14, 24, 34, and 46, respectively), and GnRH-28: GnRH delivered as in GnRH-
14, but using two, 28-d pumps (Alzet 2ML4; n = 14, 13, 13, 13, and 13 for days 0, 14, 
24, 34, and 46, respectively). The interaction of treatment by sample was not significant 
(P = 0.17) and therefore only sample (P < .0001) effects are represented. a,b,cMeans 
without a common superscript letter differ (P ≤ 0.0001) between samples. 
 
 
 
4.4.3 Pregnancy status 
Of the 22 GnRH-treated mares that became pregnant during the 56-d experiment, 
19 maintained pregnancy through day 45. The three mares exhibiting embryonic loss 
were GnRH-28 mares and embryos began to exhibit ultrasonographic changes indicative 
of pending death on days 24, 33 and 45. None of these dates were associated with 
declines in serum concentrations of progesterone or GnRH treatment removal. Two of 
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the three mares re-ovulated within 9 d following loss of pregnancy and maintained 
subsequent pregnancies through the final day of confirmation (day 45). The third mare 
remained anovulatory through her last ultrasound exam on April 21 as a result of 
formation of secondary corpora lutea during the initial pregnancy and not due to a return 
to the winter anovulatory state. By the end of the breeding season (June 30th), 92% (24 
of 26) of GnRH-treated and 86% (12 of 14) of Control mares were at least 45 days 
pregnant. Additionally, all mares were allowed to go to term, with all mares foaling 
normally and no abnormalities observed. 
 
4.4.4 Follicular responsiveness 
A small proportion of GnRH-treated (3 of 28) and Control mares (4 of 14) had 
initial follicle diameters before the start of the experiment greater than 20 mm in 
diameter. However, interval to first breeding was not reduced (P = 0.15) in mares with 
initial follicle size > 20 mm (27.7 ± 7.1) compared to mares with initial follicle size ≤ 20 
mm (39.6 ± 3.5; Figure 4.3). No differences (P = 0.90) were observed between GnRH-
14 and GnRH-28; thus, the treatment groups were pooled for further comparisons to 
controls. The relationship between initial follicle size and interval to first breeding was 
not significant (P = 0.15; y = -1.918x + 88.37; R2 = 0.17) in Control mares but tended to 
be significant (P = 0.09; y = -1.3097x + 40.924; R2 = 0.11) in GnRH treated mares (Fig. 
4.3). Multiple ovulations were not evident in any of the mares involved in this study. 
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Fig. 4.3. Correlation between initial follicle size (mm; x-axis) and interval to first 
breeding (days; y-axis) for mares in GnRH therapeutics trial. Mare treatments were 
control: untreated (n = 14; y = -1.918x + 88.37; R2 = 0.17; P = 0.15), GnRH-14: GnRH 
delivered subcutaneously in saline at a rate of 100 μg/h for 8 wk (Feb. 1 – Mar. 29) using 
four consecutive 14-d pumps (Alzet 2ML2; n = 14), and GnRH-28: GnRH delivered as 
in GnRH-14, but using two, 28-d pumps (Alzet 2ML4). GnRH treatments did not differ 
(P = 0.90) and therefore data are pooled in this figure (n = 28; y = -1.3097x + 40.924; R² 
= 0.11; P = 0.09).  
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4.5 Discussion 
Results of the current study illustrate that continuous, subcutaneous infusion of 
native GnRH (100 µg/h) is a highly-effective approach for accelerating onset of 
reproductive transition, ovulation, and pregnancy in mares in deep winter anovulation. 
The marked increase in pregnancy rate was realized using both AI and natural service 
under standard breeding farm conditions typical of those found in North America and 
globally. Using this approach, once a large follicle (35 mm) was attained using 
continuous GnRH infusion, mares were bred and an ovulation-inducing dose of hCG 
was administered at the time of breeding. 
Although a number of previous reports have demonstrated the ability of 
continuously-infused, native GnRH to initiate follicular development and ovulation in 
mares in deep winter anestrus (Johnson, 1987; Becker and Johnson, 1992), breeding 
studies conducted in New Zealand focused on mares in late reproductive 
transition/shallow anestrus (Hyland et al., 1987; Hyland and Jeffcott, 1988). Therefore, 
to our knowledge, the work reported herein is the first demonstrating the ability to 
successfully incorporate such a strategy through successful pregnancy in mares in deep 
winter anestrus. Also, using GnRH agonist injected twice daily, other investigators have 
induced follicular development and ovulation, and accelerated the timing of pregnancy 
in winter anestrous mares (McCue et al., 1992); however, when GnRH agonist was 
administered in a practical manner (continuously) the treatments were not effective 
because of apparent pituitary desensitization (Bergfelt and Ginther, 1992; Fitzgerald et 
al., 1993; Mumford et al., 1994). Hence, the value of the current work is the unequivocal 
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demonstration that the continuous, subcutaneous infusion of the native hormone, when 
began well in advance of the onset of vernal transition, is a highly efficacious approach 
for accelerating the breeding season by 30 to 60 days. 
An important aspect associated with GnRH treatments that accelerate pregnancy 
in the winter anovulatory mare is that related to corpus luteum function and the 
maintenance of pregnancy. As shown in an accompanying manuscript (Thorson et al., 
2010), if mares are treated continuously with GnRH for 28 d, beginning in early 
February, a rapid decline in circulating LH and resumption of winter anovulation occurs 
at treatment withdrawal in non-bred mares. To the contrary, if mares are treated for 28 d 
beginning in early March, ovarian cycles continue unabated following cessation of 
treatment, as mares are approaching the natural breeding season at this time. These 
findings pose the concern that subnormal luteal function and pregnancy loss could 
potentially occur if mares in February or earlier are bred and conceive during GnRH-
induced cycles in which ovulation is allowed to occur spontaneously. Hyland and 
Jeffcott (Hyland and Jeffcott, 1988) addressed this issue to some extent in a small 
number of mares treated continuously with GnRH during late transitional anestrus. 
Pregnancy was maintained through at least day 45 of gestation in 4 of 5 GnRH-treated 
mares. However, when mares in deep winter anestrus were treated with twice daily 
GnRH agonist injections (McCue et al, 1992 Bergfelt and Ginther, 1992), different 
results were observed, depending upon time of treatment onset and management of the 
preovulatory follicle. In the work by Bergfelt and Ginther (1992), mares treated with 
twice daily injections of deslorelin in February became pregnant (64%); however, this 
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population exhibited a very high rate of embryonic loss (64%). Yet, mares treated 
similarly in April responded well (71% pregnancy rate) and embryonic losses were 
reduced (20%). However, McCue et al (1992), using twice daily injections of another 
GnRH agonist (buserelin) in deep winter anestrous mares, reported high pregnancy rates 
(> 70%) and only a 7% embryonic loss. In that study, when a preovulatory follicle was 
detected in response to GnRH agonist treatment, mares were induced to ovulate using 
hCG. In the current study using continuous infusion of native GnRH, ovulation of the 
preovulatory follicle was also induced with hCG. In our experiment, only 3 of 25 GnRH-
treated, pregnant mares failed to maintain pregnancies to term. Collectively, we interpret 
these findings to indicate that mares responding to continuous GnRH treatments early in 
the calendar year (February or earlier) are at risk for developing subnormal luteal 
function and pregnancy loss unless the preovulatory follicle is induced to ovulate using 
hCG or an ovulatory dose of a commercially-available GnRH agonist (e.g., Sucramate). 
The latter ensures an adequate gonadotropic environment to support normal CL 
formation. Although the question needs further clarification, current evidence indicates 
that the amount of circulating LH needed to develop a preovulatory follicle and 
spontaneous ovulation/luteinization may be much less than that needed for optimal luteal 
formation and function. 
In the current study, there was no indication of subnormal luteal function in 
GnRH treated mares. In fact, mean serum concentrations of progesterone were similar 
(GnRH-28) or significantly greater (GnRH-14) during the luteal phases of GnRH-treated 
mares than in the control mares, and were typical of those observed during the natural 
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breeding season (Ginther, 1992; Nett et al., 1976). Bergfelt and Ginther (1992) reported 
that mares with minimal ovarian activity at initiation of GnRH treatment where more 
likely to develop dysfunctional CL but in that study mares were allowed to ovulate 
spontaneously. Thus, as noted earlier, the gonadotropic environment immediately 
preceding ovulation may play a key role in CL competence within ovarian cycles outside 
of the natural breeding season. Gonadotropic requirements of the equine CL have not 
been studied as extensively as in other species. However, in other female mammals, 
adequate LH support during ovulation and early development of the CL appears to be a 
key requirement (Astwood, 1941; Spies et al., 1967; Vande Wiele et al., 1970), whereas 
the amount of circulating LH thereafter is of lesser relevance (Snook et al., 1969; 
Juengel et al., 1995). Although 3 GnRH-treated mares experienced embryonic loss by 
day 45 of pregnancy in the current study, there was no measurable decline in serum 
concentrations of progesterone until after death of the embryos. Deficiencies in serum 
progesterone concentrations during pregnancy, defined as < 2.5 ng/mL (Douglas et al., 
1985), was not observed in the current experiment but was a notable feature of 
pregnancy loss in a previous study using a GnRH agonist (Bergfelt and Ginther, 1992). 
Responsiveness of mares to exogenous native GnRH treatment in the present 
study was not enhanced in mares with initial follicle diameter greater than 20 mm 
compared to mares with initial follicle diameter less than 20 mm, which is similar to our 
previous observations (Thorson et al., 2010). Other earlier reports have indicated that 
size of the largest follicle at treatment onset has a major influence on timing and 
frequency of ovarian responses (Bergfelt and Ginther, 1992; Ginther and Bergfelt, 
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1990). Perhaps the tendency for mares with larger follicles at the start of treatment to 
respond more rapidly than small follicles was related to the concentrations of LH 
achieved with particular treatments. 
Multiple ovulations were not observed in GnRH treated mares in the current 
work as reported by others during the winter anovulatory season (McCue et al., 1992; 
Ginther and Bergfelt, 1990), spring transition (Raz et al., 2009), and breeding season 
(Fitzgerald et al., 1993) using potent GnRH agonists. Native GnRH has also been shown 
to induce multiple ovulations during the anovulatory season. However, this was 
observed when treatments were delivered intravenously in either a continuous or 
pulsatile manner (Becker and Johnson, 1992; Johnson and Becker, 1988) but not when 
delivered subcutaneously (Thorson et al., 2010; Velez et al., 2008). Another factor that 
may play a role is breed-type of mares involved. Since Quarter Horse mares have a 
lower natural incidence of multiple ovulations compared to both Thoroughbreds and 
Standardbreds, it is possible that breed or breed type may contribute to the variability 
observed for this response (Ginther et al., 1982). Also, Ginther and Bergfelt (1990) 
reported a greater frequency of multiple ovulations (64%) with the presence of a follicle 
greater than 25 mm at treatment initiation, while Raz et al. (2009) assigned mares to 
treatments only after development of a follicle greater than 25 mm and reported a 7% 
multiple ovulation rate. 
In conclusion, continuous treatment of winter anovulatory mares with native 
GnRH at a rate of 100 µg/h beginning in early-February is an effective means to 
accelerate the Julian day of pregnancy and support primary and secondary corpora luteal 
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development and function to maintain pregnancy following treatment withdrawal. 
Further, interval to first 35 mm follicle, breeding, ovulation, and pregnancy was similar 
within the two groups of GnRH-treated mares (2ML2 vs 2ML4 pumps). However, 
because of the need for minor surgery to apply these pumps, it is highly unlikely that 
such devices will be employed routinely in the breeding industry. Thus, development of 
a user-friendly and commercially-available platform (e.g., depot technology) to 
strategically deliver native GnRH in a continuous manner remains in development. 
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CHAPTER V 
HYPOTHALAMIC DISTRIBUTION, ADENOHYPOPHYSEAL RECEPTOR 
EXPRESSION, AND LIGAND FUNCTIONALITY OF RF-AMIDE RELATED 
PEPTIDE 3 IN THE MARE DURING THE BREEDING AND NON-BREEDING  
SEASONS 
 
 
 
5.1 Synopsis 
RF-amide related peptide 3 (RFRP3), the mammalian homologue of avian 
gonadotropin-inhibitory hormone (GnIH), has been shown to negatively regulate the 
secretion of LH and may contribute to reproductive seasonality in some mammalian 
species. Herein, we examined the presence and potential role of the RFRP3-signaling 
system in regulating LH secretion in the mare during the breeding and non-breeding 
seasons. Hypothalamic RFRP3 mRNA was detected at the level of the dorsomedial 
nucleus (DMH) and paraventricular nucleus (PVN), but expression did not change with 
season. A greater number of RFRP3-expressing cells were observed throughout the 
rostral-caudal extension of the DMH. Further, adenohypophyseal expression of the 
RFRP3 receptor (GPR147) during the winter anovulatory season did not differ from that 
during either the follicular or luteal phases of the estrous cycle. When tested in vitro 
using adenohyphyseal cell culture, or in vivo during both the breeding and non-breeding 
seasons, neither equine nor ovine sequences for RFRP3 suppressed basal or GnRH-
mediated release of LH. However, infusion of RF9, an RFRP3 receptor-signaling 
antagonist, into seasonally-anovulatory mares induced a robust increase in secretion of 
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LH both before and following continuous treatment with GnRH. Collectively, these 
results indicate that the cellular machinery associated with RFRP3 function is present in 
the equine hypothalamus and adenohypophysis. However, evidence for functionality of 
the RFRP3 signaling network was only obvious when an antagonist of receptor signaling 
was employed. As GnRH responsiveness was not affected by RF9, results suggest 
influence at the GnRH neuronal level to stimulate or disinhibit secretion of GnRH. 
 
5.2 Introduction 
Reproductive seasonality in the equine species has been studied for several 
decades. Transition from the breeding to non-breeding season is characterized by a 
marked decline in synthesis and release of anterior pituitary LH, and the cessation of 
ovulatory cycles. However, photoperiod-driven signaling pathways in the hypothalamic-
hypophyseal axis that underlie this process have not been fully elucidated (Williams et 
al., 2012). 
Limited studies by Alexander and Irvine (1986), utilizing the intercavernous 
sinus cannulation (ICS) technique, and others using hypothalamic push-pull perfusion 
(Sharp and Grubaugh, 1987), have indicated that the secretion of GnRH is decreased 
during the winter anovulatory period, similar to that observed during the non-breeding 
seasons of other seasonal breeders (Barrell et al., 1992). Moreover, when seasonally 
anovulatory mares are infused hourly (Johnson, 1987; Becker and Johnson, 1992) or 
continuously (Becker and Johnson, 1992; Hyland and Jeffcott, 1988; Collins et al., 2007) 
with native GnRH, anterior pituitary secretion of LH is increased, follicular development 
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follows, and spontaneous or induced ovulations occur at a high frequency. Thus, 
regulation of the secretion or action of GnRH appears to be one of the most important 
factors regulating seasonality in this species. 
A potential role for inhibitory neuropeptides in this process has also been 
proposed (Smith et al., 2012). These would act theoretically by impairing GnRH 
neuronal activity or through direct suppression of secretion of LH by the gonadotrope. 
Tsutsui et al. (2000) was the first to report on the existence of a novel hypothalamic 
neuropeptide with inhibitory effects on secretion of LH in quail. The molecule contained 
a C-terminal LPLRF-amide sequence and was coined gonadotropin-inhibitory hormone 
(GnIH). Three RF-amide related peptides (RFRP1, 2 and 3) and two G-protein coupled 
receptors (GPR147/NPFFR1 and GPR74/NPFFR2) have been characterized in 
mammalian species. In rats, hamsters, sheep, and cattle, RFRP3 has been shown to 
suppress the secretion of LH (Kriegsfeld et al., 2006; Clarke et al., 2008; Kadokawa et 
al., 2009; Pineda et al., 2010) as well as adenohypophyseal responsiveness to GnRH 
(Clarke et al., 2008; Kadokawa et al., 2009; Pineda et al., 2010) in a dose-dependent 
manner. Thus, if RFRP3 regulates seasonality in mammals, it may do so in part by direct 
effects on the adenohypophysis. However, its role in mammalian reproduction continues 
to remain controversial, as the number of reports showing functional effects (Kriegsfeld 
et al., 2006; Clarke et al., 2008; Pineda et al., 2010) has been offset by an equally 
significant number showing little or no effect in rats, hamsters and sheep (Murakami et 
al., 2008; Anderson et al., 2009; Rizwan et al., 2009; Ancel et al., 2012; Caraty et al., 
2012; Ubuka et al., 2012). 
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The existence and function of RFRP3 in the mare has not been reported. 
Experiments reported herein addressed the hypotheses that expression of genes for 
RFRP3 and its receptor occurs within the equine hypothalamus and adenohypophysis, 
respectively, and that the predicted sequence for equine RFRP3 (eRFRP3) functionally 
regulates secretion of LH in the mare. 
 
5.3 Materials and methods 
All animal-related experiments were approved by the Institutional Agricultural 
Animal Care and Use Committee (IAACUC) of the Texas A&M University System. 
 
5.3.1 RFRP3 sequence, synthesis and application 
Using primers designed for the eRFRP gene, a partial cDNA sequence of 
approximately 420 bp was amplified by PCR and cloned into a vector. Based on cDNA 
sequencing, the predicted sequence of the eRFRP3 has been determined to be Ile-Pro-
Asn-Leu-Pro-Gln-Arg-Phe-NH2. The peptide synthesized for studies reported herein 
have been validated by high-performance liquid chromatography and mass spectral 
analysis (98% purity and molecular weight of 983). Doses of eRFRP3 used in the 
following experiments were determined by doses used previously in other species such 
as sheep (Clarke et al., 2008) and rats (Murakami et al., 2008). 
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5.3.2 Experiment 1. Seasonal expression of the eRFRP gene 
5.3.2.1 Animal model and experimental design 
Twelve mares with histories of regular reproductive cycles were used to 
determine whether season influences the expression of eRFRP. Circulating 
concentrations of progesterone and transrectal ultrasonography were used to confirm 
reproductive status before the beginning of the experiment. Four mares were euthanized 
during the winter anovulatory season (December-January) once anovulatory status was 
confirmed via serum progesterone and ultrasonography. The remaining eight mares were 
euthanized during the follicular (n = 4) and luteal (n = 4) phases of the estrous cycle 
within the natural breeding season (May-July). After euthanasia, a tissue block 
containing the hypothalamus was dissected out, rapidly frozen in liquid nitrogen vapor, 
and stored at -80o C. Coronal sections (20 μm) were cut on a cryostat and a series of 
every 10th section was used for detection of eRFRP3 precursor mRNA by isotopic in situ 
hybridization as previously described (Redmond, 2010). A 35S-labeled riboprobe was 
synthesized using the equus caballus RFRP cDNA and processed as described 
previously (Mitchell and Ing, 2003) using promoter specific primers. Controls included 
hybridization with sense probe. The location of eRFRP mRNA-containing neurons were 
identified under dark- and bright-field microscopy based on density of silver grains 5x 
above background density. Cell counts were performed in comparable sections within 
the paraventricular nucleus (PVN; 5 sections) and the dorsomedial nucleus of the 
hypothalamus (DMH; 10 sections) of each mare. 
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5.3.2.2 Hormone assays 
Serum concentrations of progesterone were determined using a commercial RIA 
kit (Coat-A-Count; Diagnostic Products Corporation, Los Angeles, CA) as reported 
previously from this laboratory (Williams et al., 2007). All samples were analyzed for 
progesterone in a single assay with minimum detectable concentration of 0.1 ng/mL and 
a mean intraassay CV of 6.3%. 
 
5.3.2.3 Statistical analysis 
The main effect of reproductive status on number of cells containing eRFRP3 
mRNA were compared between the groups using the Proc GLM procedure of the 
Statistical Analysis System (SAS; SAS Inst. Inc., Cary, NC). Source of variation was 
reproductive status. The Least Squares Means procedure was used to compare means if 
significant differences were detected. 
 
5.3.3 Experiment 2. Adenohypophyseal expression of eGPR147 (RFRP3 receptor) 
during the breeding and non-breeding seasons 
5.3.3.1 Animal model and experimental design 
Adenohypophyses of mares used for Experiment 1 were used. Adenohypophyses 
were snap frozen in liquid nitrogen and stored at -80oC. Cellular RNA was isolated from 
adenohypophyseal tissue and reverse transcribed (RT) to cDNA as described previously 
(Allen et al., 2012). Initially, we performed PCR reactions to amplify equine GPR147 
(eGPR147) from adenohypophyseal tissue using primers that successfully amplified 
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GPR147 from the hypothalamus. Following successful PCR amplifications, real-time 
RT-PCR was performed to quantify eGPR147 gene expression in the adenohypophysis 
of mares (Experiment 1) during the winter anovulatory season (n = 4; December-
January) and during the follicular (n = 4) and luteal (n = 4) phases of the estrous cycle 
within the natural breeding season (May-July). Primers used in the real-time RT-PCR 
analysis were designed based on the sequence of eGPR147 amplified from equine 
hypothalamus. Reactions were performed in triplicate for each cDNA sample as 
described previously (Allen et al., 2012). Controls include the verification of absence of 
primer-dimer amplification and genomic DNA carryover, and estimation of melting 
temperature of PCR products. 
 
5.3.3.2 Statistical analysis 
Real-time RT-PCR data were analyzed after normalizing mean gene expression 
to a reference gene (RPS20). The main effects of reproductive status on GPR147 gene 
expression were compared between the groups using the Proc GLM procedure of SAS. 
Source of variation was reproductive status. The Least Squares Means procedure was 
used to compare means if significant differences were detected. 
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5.3.4 Experiment 3. Effects of eRFRP3 on GnRH-mediated secretion of LH from 
adenohypophyseal cell culture 
5.3.4.1 Animal model and experimental design 
Adenohypophyses were harvested from five mares after euthanasia and placed 
directly on ice. Since pituitaries were collected during the winter, all mares received 
Alzet osmotic pumps delivering GnRH (100 µg/h) for 12-18 d prior to euthanasia to 
stimulate synthesis of LH in gonadotropes. Adenohypophyseal cells were dispersed 
enzymatically, plated in 6-well plates containing 300,000 cells/well, and cultured in 
Dulbecco’s modified Eagle’s medium following procedures described previously (Welsh 
et al., 1986). On day 4 (after cells reach approximately 70% confluence), cells were 
incubated with media alone (control), media containing GnRH (10-8 M) only (positive 
control), or media containing GnRH (10-8 M) plus eRFRP3 (10-6, 10-7, 10-8, 10-9, and 10-
10 M) for 4 h. Each treatment was applied to at least 3 wells and 5 independent 
replications were performed. Additional cells were also treated with GnRH (10-8 M) plus 
ovine RFRP3 (oRFRP3; 10-6 and 10-9 M) for 4 h to test a preparation that has been 
shown previously to inhibit release from ovine gonadotropes (Clarke et al., 2008) as well 
as a preparation that has been shown previously to have no effect in ovine gonadotropes 
(Dr. Terry Nett, Colorado State University, personal communication). At the end of each 
4-h incubation period, culture media was harvested and stored at -20oC. 
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5.3.4.2 Hormone analyses 
Concentrations of LH in media were analyzed by double antibody RIA, as 
validated previously in this laboratory (Williams et al., 2007). A highly-purified equine 
LH (eLH AFP-5130A) preparation was used for both iodinated tracer and standards. An 
anti-eLH antiserum (AFP-240580) was used at a dilution of 1:120,000 which yielded 
28.3% binding on average at B/O. The sensitivity of the LH assays were 0.1 ng/mL and 
mean intra- and interassay CV were 7.2% and 3.7%, respectively. 
 
5.3.4.3 Statistical analysis 
The Proc GLM procedure of SAS was used to determine main effects of RFRP3 
treatment on differences in media LH concentrations. Sources of variation were 
treatment, replicate, and treatment x replicate interaction. The Least Squares Means 
procedure was used to compare means if significant differences were detected. 
 
5.3.5 Experiment 4. Stimulatory effects of an RFRP3 receptor-signaling antagonist 
(RF9) on secretion of LH during the winter anovulatory period 
5.3.5.1 Animal model and experimental design 
Ten winter anovulatory mares were assigned randomly to one of two treatments: 
Control or RF9 (n = 5/treatment). RF9 (Adamantanecarbonyl-Arg-Phe-NH4), a selective 
antagonist for the NPFF receptors, was synthesized by GeneCust Europe (Dudelange, 
Luxembourg). On experimental day 0, jugular blood samples were collected at 10 min 
intervals for 5 h beginning 1 h before treatment. Intravenous injections of saline or RF9 
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(0.2 mg/kg BW) were administered at hour 1, 2, and 3. Mares were then treated 
continuously with GnRH (100 µg/h) for 72 h via subcutaneous osmotic pumps, an 
approach uniquely effective in the equine for stimulating adenohypophyseal synthesis of 
LH. On experimental day 4 (12 h after pump removal), jugular blood samples were 
collected at 10 min intervals for 6 h beginning 1 h before treatment. Intravenous 
injections of saline or RF9 (0.4 mg/kg BW) were administered at 1 and 2 h. A GnRH 
injection (250 µg, intravenously) at hour four was conducted to test adenohypophyseal 
responsiveness. At the end of the sampling periods, plasma was harvested and stored at -
20oC until determination of plasma LH concentrations using a previously validated 
equine LH RIA (Williams et al., 2007). 
 
5.3.5.2 Hormone analyses 
Radioimmunoassay for LH was the same as for previous experiments. Mean 
intra-assay CV was 7.4%, with all samples analyzed in one assay. 
 
5.3.5.3 Statistical analysis 
The GLM procedure of SAS was used to determine main effects of RF9 
treatment on differences in plasma concentrations of LH. Sources of variation were 
treatment, period, and treatment x period interaction. The Least Squares Means 
procedure was used to compare means when significant differences were detected. Area  
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under the curve was calculated using the Trapezoid Rule. The Proc T-test procedure of 
SAS was used to determine main effects of GnRH-injection on differences in plasma LH 
concentrations. 
 
5.4 Results 
5.4.1 Experiment 1. Seasonal expression of the eRFRP gene 
Hypothalamic RFRP mRNA was detected within the DMH and PVN (Fig. 5.1). 
In the PVN, RFRP-expressing cells were distributed sparsely. A greater number of 
RFRP-expressing cells was observed throughout the rostral-caudal extension of the 
DMH. However, RFRP-expressing cell count within the PVN and DMH during the 
winter anovulatory season (PVN, 53.5 ± 20.7; DMH, 314.3 ± 59.0) did not differ (P ≥ 
0.44) from that during either the follicular (PVN, 39.0 ± 16.1; DMH, 248.5 ± 89.1) or 
luteal (PVN, 46.3 ± 32.2; DMH, 172.5 ± 72.2) phases of the estrous cycle. 
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Fig. 5.1. RFRP-expressing cells mapped in the paraventricular nucleus (A) and 
dorsomedial nucleus of the hypothalamus (DMH; B) visualized by in situ hybridization. 
RFRP-expressing cells observed in the mare brain at low (C; 100 µm scale bar) and high 
(D; 20 µm scale bar) magnification within the DMH. Fornix (FX), mammillothalamic 
tract (MT), optic tract (OT), and third ventricle (3V).  
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5.4.2 Experiment 2. Adenohypophyseal expression of eGPR147 (RFRP3 receptor) 
during the breeding and non-breeding seasons 
Adenohypophyseal expression of GPR147 was evident during the winter 
anovulatory season, as well as during the follicular and luteal phases of the estrous cycle. 
However, expression during the winter anovulatory season did not differ (0.74 ± 0.09; P 
= 0.60) from that of either the follicular (1.11 ± 0.34) or luteal (0.88 ± 0.26) phases of 
the estrous cycle when normalized to a pooled reference sample. 
 
5.4.3 Experiment 3. Effects of eRFRP3 on GnRH-mediated secretion of LH from 
adenohypophyseal cell culture 
Adenohypophyseal cells cultured with GnRH increased (P < 0.0001) media 
concentrations of LH 7-fold (17.5 ± 1.7 ng/mL) compared to vehicle (2.6 ± 0.3 ng/mL; 
Fig. 5.2). However, eRFRP3 failed to reduce adenohypophyseal responsiveness to 
GnRH at any dose tested, as concentrations of LH in eRFRP3 + GnRH-containing media 
did not differ (P ≥ 0.18; Fig. 5.2) from the positive control media stimulated with GnRH 
alone. Furthermore, oRFRP3 preparations previously used to suppress 
adenohypophyseal responsiveness to GnRH in a dose-dependent manner in ovine 
pituitary cultures was ineffective in equine adenohypophyseal cultures (Fig. 5.2). 
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Fig. 5.2. Luteinizing hormone concentrations in culture media collected from winter 
anovulatory mares. Mares were fitted subcutaneously with Alzet osmotic pumps (100 µg 
GnRH/h for 12-18 d) to stimulate synthesis of LH by gonadotropes. Ovine RFRP3 was 
synthesized by: Auspep Pty, Ltd.† and United Biochemical Research, Inc.‡. Number of 
replicates: vehicle and GnRH n = 16; eRFRP3 n = 14-15; oRFRP3: Auspep Pty, Ltd. n = 
13-15, United Biochemical Research, Inc. n = 7. 
 
 
 
5.4.4 Experiment 4. Stimulatory effects of RF9 (RFRP3 receptor-signaling antagonist) 
on secretion of LH during the winter anovulatory period 
Mean secretory patterns of LH observed in plasma samples collected from 
control and RF9-treated mares are presented in Fig. 5.3 and mean plasma concentrations 
of LH for pre- and post-treatment periods are presented in Fig. 5.4. On day 0, RF9 
induced a robust and sustained increase (P < 0.0001) in circulating concentrations of LH 
relative to Controls (Fig. 5.3A and Fig. 5.4A). Continuous GnRH infusion at 100 µg/hr 
increased (P = 0.001) mean LH concentrations from day 0 (0.21 ± 0.03 ng/mL) to day 4 
(0.33 ± 0.03 ng/mL) in Control and RF9 treated mares. On day 4, RF9 caused a 
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sustained increase (P = 0.0002) in circulating concentrations of LH relative to Controls 
(Fig. 5.3B and Fig. 5.4B). Intravenous injection of GnRH induced LH release in both 
groups, but responsiveness to GnRH as determined by area under the curve did not differ  
(P = 0.91) between Control (54.9 ± 9.8) and RF9 (57.1 ± 17.5) treatments. 
 
 
 
 
 
Fig. 5.3. Least squares means concentrations of LH in control (dashed line) and RF9 
(solid line)-treated mares on day 0 (pre-GnRH infusion; A) and day 4 (post-GnRH 
infusion; B). Black arrows indicate times of saline or RF9 (0.2 or 0.4 mg/kg/injection on 
day 0 and 4, respectively) injections on each day of the experiment.  
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Fig. 5.4. Mean plasma concentrations of LH for pre- and post-treatment periods on day 0 
(pre-GnRH infusion; A) and day 4 (post-GnRH infusion; B). The pre-treatment period 
consisted of blood samples collected before RF9/saline treatment, whereas the post-
treatment period consisted of a 4 h sampling period on day 0 and a 3 h sampling period 
on day 4. Period x treatment interaction P < 0.0001. 
 
 
 
5.5 Discussion 
Results of experiments presented herein indicate that the genomic machinery 
associated with hypothalamic eRFRP3 and adenohypophyseal receptor ligand signaling 
is present in the mare. However, mRNA expression for the ligand and receptor did not 
appear to fluctuate with season or stage of the estrous cycle. Nonetheless, a RFRP3 
receptor-signaling antagonist (RF9) was shown to create robust stimulatory effects on 
secretion of LH during the non-breeding season which contrasted surprising inabilities of 
both the eRFRP3 (predicted) sequence and ovine RFRP3/GnIH to inhibit secretion of 
LH (Prezotto, 2012). 
In initial experiments, we hypothesized that the number of neurons expressing 
RFRP3 in the hypothalamus of the mare would be elevated during the winter 
anovulatory period and luteal phase of the estrous cycle when photostimulation and 
circulating estradiol concentrations are minimized. However, since changes in RFRP3 
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expression did not differ with season or reproductive phase, functional regulation of the 
RFRP3 system in the mare may be gated further down-stream. This could potentially 
include differential rates of translation, vesicular exocytosis at neuronal terminals, or 
receptor availability on target tissues. Both GnIH and its mammalian homologue, 
RFRP3 have been linked to the regulation of reproductive seasonality in other seasonal 
breeding species (avian, rodents, and ovine), with marked changes in GnIH/RFRP3 
expression and peptide accumulation observed in the hypothalamus in response to 
changing photoperiod (Tsutsui et al., 2000; Ubuka et al., 2005; Clarke et al., 2008; Revel 
et al., 2008). During the photostimulatory periods of these species, estradiol 
concentrations fluctuate with follicular growth to communicate feedback to the medial 
basal hypothalamus. Another member of the RF-amide family, kisspeptin, acts in a 
contrasting manner to that of GnIH/RFRP3, and exhibits increased hypothalamic mRNA 
expression and protein concentration under the influence of estradiol (Kinoshita et al., 
2005); however, the role of estradiol in GnIH/RFRP3 has not been fully elucidated 
(Kriegsfeld et al., 2006; Popa et al., 2008; Molnar et al., 2011). 
As noted earlier, RFRP3 has been shown in several experiments to suppress the 
secretion of LH (Kriegsfeld, 2006; Clarke et al., 2008; Kadokawa et al., 2009; Rizwan et 
al., 2009) in rats, hamsters, sheep, and cattle, as well as to directly reduce 
adenohypophyseal responsiveness to GnRH, in a dose-dependent manner (Hinuma et al., 
2000; Kriegsfeld et al., 2006; Clarke et al., 2008). Based on results from cell culture 
studies (Ciccone et al., 2004; Ubuka et al., 2006; Clarke et al., 2008; Murakami et al., 
2008), RFRP3 appears to be able to regulate secretion of LH through direct inhibitory 
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effects on gonadotropes. In addition, LHβ and FSHβ gene expression is reduced in 
GnRH-stimulated ovine pituitary cells treated with RFRP3 (Clarke et al., 2008). This 
functionality is bolstered by anatomic data from both birds (Bentley et al., 2003; Ukena 
et al., 2003; Osugi et al., 2004) and mammals (Clarke et al., 2008). In sheep, cell bodies 
containing RFRP3/GnIH are located within the DMH and PVN, with PVN cell bodies 
also projecting towards the neurosecretory zone of the median eminence (Clarke et al., 
2008). We have observed a similar anatomic pattern in the mare (Amstalden, Bentley 
and Williams, unpublished observations). However, in our experiments, 
adenohypophyseal expression of GPR147/NPFF1 during the winter anovulatory season 
did not differ from that during either the follicular or luteal phases of the estrous cycle. 
Thus, the hypothesis that expression GPR147/NPFF1 is up-regulated during the winter 
anovulatory season, which would serve to drive a seasonal reduction in gonadotrope 
responsiveness to GnRH and reduce circulating concentrations of LH, was not 
supported. Moreover, functional studies using primary anterior pituitary cell cultures 
failed to support the hypothesis that RFRP3 reduces the responsiveness of gonadotropes 
to GnRH in the mare, as neither equine nor ovine RFRP3 reduced secretion of LH. 
These results are in clear contrast to those obtained with primary adenohypophyseal cell 
cultures from several other species, including rats (Murakami et al., 2008), poultry 
(Ciccone et al., 2004), and sheep (Clarke et al., 2008). 
In a subsequent series of in vivo experiments, Prezotto (2012) set out to 
determine if RFRP3, when administered peripherally, decreases circulating 
concentrations of LH during the follicular phase of the estrous cycle and in seasonally 
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anovulatory mares pre-treated with GnRH to stimulate synthesis of LH in gonadotropes. 
Results indicated that neither acute nor chronic administration of eRFRP3 at any dose 
tested, nor oRFRP3 given as a large single dose, are able to suppress episodic release, 
mean concentration, or GnRH-induced release of LH in mares (Prezotto, 2012). Earlier 
studies in male calves (Kadokawa et al., 2009) and ovariectomized ewes (Clarke et al., 
2008) indicate that RFRP3 suppressed pulsatile release of LH. However, this is in 
contrast to other reports that demonstrate neither icv nor iv RFRP3 treatments suppress 
secretion of LH in ewes (Caraty et al 2012; T.M. Nett, personal communication). A 
similar failure of RFRP3 to suppress LH has been reported in ovariectomized, estradiol-
replaced rats (Anderson et al., 2009) and ovariectomized pre-pubertal gilts (Heidorn et 
al., 2010). Further, stimulatory effects have been reported in the Syrian (Ancel et al., 
2012) and Siberian (Ubuka et al., 2012) hamster. Therefore, the role of RFRP3 in 
mammals has remained controversial as a result of the variable ability of RFRP3 to 
suppress secretion of LH. 
Importantly, an additional approach for examining the RFRP3 signaling network 
became available with the development of a selective antagonist for the NPFF receptors, 
RF9 (Simonin et al., 2006). The latter has been shown to induce a potent release of LH 
in rats, mice, and sheep when administered centrally or peripherally (Pineda et al., 2010; 
Caraty et al., 2012; Rizwan et al., 2012). In the current experiment, we tested the 
hypothesis that peripheral administration of RF9 induces secretion of LH in the winter 
anovulatory mare. Similar to results obtained in rodents and ewes (Pineda et al., 2010; 
Caraty et al., 2012; Rizwan et al., 2012), RF9 induced a marked increase in circulating 
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concentrations of LH. Furthermore, when mares were pre-treated for 72 h with GnRH to 
induce additional synthesis of LH in their seasonally-depleted pituitaries, the selective 
antagonist remained stimulatory. However, when mares were treated with a large, bolus 
dose of GnRH to induce maximum release of LH, responses did not differ between 
Control mares and those treated earlier with RF9. 
Although the specific mechanisms through which RF9 stimulates secretion of LH 
remain to be determined, the possibility exists that it is acting directly at the level of the 
GnRH neuron. To date, data from all species reported (avian, rodents, ovine, sub-
primates, humans, and equine) have demonstrated GnIH/RFRP3-immunoreactive fibers 
in close proximity to GnRH neurons (Bentley et al., 2003; Kriegsfeld et al., 2006; Ubuka 
et al., 2008; Smith et al., 2008; Qi et al., 2009; Ubuka et al., 2009a; Ubuka et al., 2009b; 
Amstalden, Williams, and Bentley, unpublished observation). Furthermore, 
GPR147/NPFF1 is expressed in GnRH neurons in birds (Ubuka et al., 2008) and rodents 
(Rizwan et al., 2012). Functional support for this hypothesis includes the reduction in 
firing activity (Ducret et al., 2009; Ubuka et al., 2009b; Wu et al., 2009) and immediate 
early gene expression in GnRH neurons (Anderson et al., 2009) with administration of 
RFRP3. In addition, RFRP3/GnIH directly inhibited GnRH neuronal activity by 
hyperpolarizing the neuronal membrane through K+ conductance in dwarf gourami 
(Saito et al., 2010) allowing for the down-stream reduction in LH synthesis and 
secretion. 
Although RFRP3 appears to function through GPR147 expressed within both the 
hypothalamus and pituitary (Hinuma et al., 2000; Ubuka et al., 2009b), functional 
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variability associated with RFRP3 effects has resulted in uncertainty regarding its 
mechanism of action in mammals. It is well documented that mammalian gonadotropes 
couple GnRH receptor with Gαq/11 to stimulate phospholipase C (PLC), resulting in the 
generation of inositol triphosphate (IP3) and diacylglycerol (DAG; Naor, 2009). These 
two components then activate protein kinase C (PKC) and trigger calcium mobilization 
to induce phosphorylation of mitogen-activated protein kinases (MAPKs; Naor, 2009). 
Mechanisms proposed in mammals to transmit GnIH/RFRP3 signal at the level of the 
gonadotrope ultimately result in inhibiting intracellular calcium mobilization (Clarke et 
al., 2008), the primary GnRH receptor-induced signal for gonadotrope exocytosis 
(Stojilkovic and Catt, 1992; Stojilkovic and Catt, 1995), as well as phosphorylation of 
mitogen-activated protein kinases (ERK-1/2; Sari et al., 2009) to inhibit gonadotropin 
gene expression (Haisenleder et al., 1998). Therefore, GnIH/RFRP3 effectively reduces 
GnRH-induced gonadotropin synthesis and secretion. 
In the mare, data failed to demonstrate any functional effects of RFRP3 in vivo 
(Prezotto, 2012) or in vitro. However, the emergence of RF9 as an antagonist of RFRP3 
allows for additional methods to evaluate the RFRP3 site of action and mechanism by 
which RF9 functions to antagonize the RFRP3 system. The possibility exists that RF9 
acts directly on GnRH neurons through GPR147 to antagonize the RFRP3 system. In 
fact, results indicate that the effects of RF9 are not on pituitary gonadotropes (Pineda et 
al., 2010). Further, the effects of RF9 are blocked by GnRH antagonists (Anderson et al., 
2011; Caraty et al., 2012). In accordance with previous observations, RF9 induced a 
robust and sustained release of LH when administered to the mare peripherally. Further, 
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as secretion of LH in mares was induced rapidly, RF9 likely acts centrally in the rapid 
secretion of GnRH. Unlike the uncertainty regarding the functional role of RFRP3 in 
mammals, RF9 induces secretion of LH in all mammals studied (Pineda et al., 2010; 
Caraty et al., 2012; Rizwan et al., 2012) illustrating indirectly that the mammalian 
RFRP3 system is functional. 
In conclusion, the current data indicates that the cellular machinery associated 
with RFRP3 function is present in the equine hypothalamus and adenohypophysis, 
although no evidence emerged to support a seasonal regulation of genes for the 
hypothalamic peptide or its receptor in the pituitary. Thus, the functional role of RFRP3 
during different reproductive states in the mare remains unclear. Nonetheless, using 
RF9, an RFRP3 receptor antagonist, we have provided the first evidence that the RFRP3 
signaling network is functional in the horse. The basis for the failure of RFRP3 itself to 
act in an inhibitory fashion on secretion of LH remains undetermined.  
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CHAPTER VI 
CONCLUSIONS 
 
 
 
The horse possesses unique reproductive endocrine features that make them both 
a challenge to manage as well as amenable to unorthodox therapies. This is 
demonstrated in research conducted under the first over-arching aim that indicates that 
the robustness of anterior pituitary and ovarian responses of winter anovulatory mares to 
continuous GnRH treatments are similar whether initiated in early February or early 
March in North America. However, since strategies to accelerate Julian day foaling dates 
are the primary concern of breeders, it would seem plausible to begin such treatments in 
early February rather than in March. If this approach is chosen and mares are allowed to 
ovulate spontaneously, without any additional gonadotropic support, it appears that 
continuous GnRH therapy would need to continue to the end of March in order to assure 
continued cyclicity in the absence of pregnancy. However, prevailing evidence indicates 
that continued treatment following ovulation may not be necessary if mares are induced 
to ovulate with additional gonadotropic support (e.g., hCG or surge-inducing treatment 
with GnRHa). Such a strategy would help to ensure normal luteal function and thus 
maintenance of pregnancy if mares are bred. In fact, continuous GnRH treatment 
through March was used successfully in conjunction with hCG-induced ovulation. Such 
treatments provide an effective means to accelerate the Julian day of pregnancy and 
support primary and secondary corpora luteal development and function to maintain 
pregnancy following treatment withdrawal while reducing the intervals to first 35 mm 
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follicle, breeding, ovulation, and pregnancy. However, more direct tests are needed to 
determine whether continuous GnRH treatment can be terminated in a normal 
management scenario if ovulations are induced as described above as opposed to being 
allowed to occur spontaneously. Nonetheless, in spite of the biological advantage of 
native GnRH in this setting, as shown in this dissertation, its value continues to remain 
unexploited from a commercial perspective. This appears to be driven mainly by the 
current lack of a practical and efficient delivery platform that does not require minor 
surgery (e.g., injectable depot delivery), an approach currently under investigation in the 
laboratory of Dr. Gary Williams (Texas A&M AgriLife, Beeville). 
Data collected under the second over-arching aim indicate that the cellular 
machinery associated with RFRP3 function is present in the equine hypothalamus and 
adenohypophysis. This includes the presence of RFRP3 expressing neurons in the 
hypothalamus, RFRP3-containing neuronal projections towards GnRH neurons and the 
median eminence (Amstalden, Bentley, and Williams, unpublished observations), and 
presence of RFRP3 receptor in the hypothalamus (Amstalden and Williams, preliminary 
data) and adenohypophysis. However, the functional role of this hypothalamic peptide 
during different reproductive states in the mare remains unclear. Functional data 
regarding the site of RFRP3 action also remain unclear, as administration of the selective 
RFRP3 receptor antagonist (RF9) produces a robust increase in LH release in the 
transitional mare. These data are the first to illustrate such effects in a long-day breeder, 
and provide indirect evidence that RFRP3 action probably involves an inhibitory 
influence on GnRH release at the hypothalamic level. However, our laboratory has been 
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unable to demonstrate those inhibitory effects using both eRFRP3 and oRFRP3 
(Prezotto, 2012) and experiments failed to support the hypothesis that RFRP3 reduces 
the responsiveness of gonadotropes to GnRH. Notwithstanding the lack of direct 
evidence for ligand functionality or seasonal changes in expression of RFRP3 and its 
receptor in the mare, data presented within this dissertation using an RFRP3 receptor-
signaling antagonist (RF9) provide indirect evidence that the RFRP3 system is indeed 
functional in this species. Future directions to elucidate the functionality of the RFRP3 
system in the mare may involve determining secretory patterns and physiological 
concentrations of RFRP3 throughout the year. This will allow for the development of 
alternative techniques to better study and subsequently manipulate the RFRP3 system. 
Also, as neuroendocrine signaling is regulated by numerous pathways, it may prove 
fruitful to concomitantly administer other hormones (i.e., kisspeptin, sex steroids, etc.) 
with RFRP3 or RFRP3 receptor antagonists to evaluate hormone interactions and the 
ability of one pathway to suppress or work synergistically with another.  
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APPENDIX 
THEORETICAL DEVELOPMENT AND FRAMEWORK 
 
 
 
Original hypothesized model 
The RFRP3-neuronal soma (maroon) are located within the dorsomedial nucleus 
of the hypothalamus (DMH). These neurons project terminals to the external zone of the 
median eminence (ME) and secrete RFRP3 (maroon spheres) into the portal vasculature 
that drains over the adenohypophysis. Similarly, GnRH-neuronal soma (green) are 
dispersed throughout the medial basal hypothalamus, releasing GnRH (green spheres) 
into the portal vasculature. Secreted GnRH binds to membrane-bound GnRH receptors 
on gonadotropes located within the adenohypophysis. During the breeding season (long 
days), gonadotropes secrete functional amounts of LH (black arrow) to drive follicular 
development and ovulation. However, during the non-breeding season (short days), 
RFRP3 secreted within the portal vasculature acts at the level of the adenohypophysis to 
reduce gonadotrope responsiveness to GnRH. This in turn reduces the synthesis and 
secretion of LH by gonadotropes and inhibits follicular growth and ovulation during the 
non-breeding season. 
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Revised hypothesized model 
The RFRP3-neuronal soma (maroon) are distributed along a loose continuum 
from the level of the paraventricular nucleus (PVN) to the dorsomedial nucleus of the 
hypothalamus (DMH). These neurons project terminals to the external zone of the 
median eminence (ME) and towards GnRH neuronal soma and terminals (green) 
dispersed throughout the medial basal hypothalamus. Secretion of RFRP3 (maroon 
spheres) into the portal vasculature binds to GPR147, directly or indirectly inhibiting the 
secretion of GnRH (green spheres). Further, RFRP3 neuronal terminals have direct or 
indirect (dashed line) contact with GnRH soma to decrease GnRH synthesis. The 
culmination of this inhibition suppresses the secretion of GnRH into the portal 
vasculature, preventing LH synthesis and secretion (black arrow) by gonadotropes, and 
ultimately inhibiting ovarian activity during the non-breeding season (short days). 
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Merged hypothesized model 
Upon exogenous infusion of a superphysiological dose of native GnRH (solid 
green arrow), adenohypohyseal GnRH receptors bind the hormone, LH syntheis and 
secretion (solid black arrow) is driven, and ovarian activity is stimulated in the winter 
anovulatory mare. Additionally, the superphysiological dose of native GnRH may also 
be acting at the level of the hypothalmus (top dashed green arrow) or ovary (bottom 
dashed green arrow) to drive steroidogenesis and the rapid onset of estrus behavior. One 
or more of these processes release the mare from the inhibition placed on the 
reproductive axis during the non-permisive photoperiod as depicted in the “Revised 
hypothesized model” above. As a result of ovarian stimulation, steroidogenesis occurs 
and acts systemically at the hypothalamus (solid blue arrow) to induce estrus behavior 
and the adenohypophysis (dashed blue arrow) to further up-regulate the synthesis and 
secretion of LH. 
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Additional methodology  
 
 
 
Equine LH radioimmunoassay 
1. Iodinated Product: Iodination grade eLH (AFP-5130A) 
2. Antibody: Anti-equine LH (AFP-240580). Dilution 1:100,000 
3. Standards (stds): Iodination grade equine LH (AFP-5130A; 0.1 – 20.0 ng/mL) 
4. References (ref): equine LH added to equine serum 
5. RIA Procedure: 
Day 1: Begin Assay 
1. NSB – 500 μl of 1% PBS-EW (egg white) 
2. 0 Std – 500 μl of 1% PBS-EW 
3. Stds – 200 μl std + 300 μl of 1% PBS-EW 
4. Ref – 200 μl ref + 300 μl of 1% PBS-EW 
5. Unknown – 200 μl unknown sample + 300 μl of 1% PBS-EW 
6. Pipette 200 μl of PBS-EDTA + 1:400 NRS without primary antibody into 
NSB tubes only 
7. Pipette 200 μl of anti-eLH (diluted in PBS-EDTA + 1:400 NRS) into all tubes 
except NSB and TC tubes 
8. Pipette 100 μl 125I-eLH (20,000 cpm/100 μl diluted in 1% PBS-EW) into all 
tubes 
9. Vortex tubes briefly and incubate for 24 h at 4°C  
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Day 2: Add Second Antibody 
1. Pipette 200 μl of Sheep-anti-rabbit gamma globulin (SARGG; 2nd Ab) diluted 
in PBS-EDTA without NRS into all tubes except TC tubes 
2. Vortex tubes briefly and incubate for 48-72 h at 4°C 
 
Day 4: Pour Off Assay 
1. Add 3 ml ice cold PBS (0.01 M; pH 7.0) to all test tubes except TC tubes 
2. Centrifuge tubes for 1 h at 4°C at 3600 rpm 
3. Decant supernatant 
4. Count radioactivity of each tube using a gamma counter  
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Progesterone radioimmunoassay 
Single Antibody RIA Kit, Diagnostic Products Corporation, Los Angeles, CA 
1. Iodinated Product: Iodination grade hP4 
2. Antibody: Anti-human P4 coated tubes 
3. Standards: Human serum with added P4 (0.1 – 20.0 ng/mL) 
4. Reference: Human standard preparation added to bovine serum 
5. RIA Procedure: 
Day 1: begin and complete assay 
1. Pipette in non-coated polypropylene tubes 
NSB – 100 μl of 0 Std 
2. Pipette in antibody coated tubes 
0 Std – 100 μl 
Std – 100 μl 
Ref – 100 μl 
Unknowns – 100 μl 
3. Pipette 1 ml of 125I –P4 provided in the kit to all tubes including two Total Count non-
coated polypropylene tubes 
4. Vortex tubes briefly and incubate at room temperature for 3 h 
5. Pour off supernatant 
6. Count radioactivity of each tube using a gamma counter  
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Primary equine adenohypophyseal cell culture 
Collection 
1. Remove the frontal bone cap to expose the brain using a bone saw 
2. Tilt the head caudally and slowly remove the brain, cutting meninges, cranial nerves, 
and the infundibulum (close to the pituitary) to expose the pituitary gland 
3. Using a scalpel blade, make four cuts through the meninges around the pituitary gland 
4. Using a forceps, grasp a corner of the meninges and withdrawal the pituitary gland 
from the sella tursica 
5. Place the pituitary in a whirl-top bag and place on (not in) ice for transport to the lab 
 
Tissue Processing 
1. Place pituitary gland in a sterile pitri dish and rinse with 1X DMEM 
2. Utilizing a sterile scalpel blade, forceps, and scissors, remove the meninges and 
neurohyphoshesis 
3. Place pituitary gland in sterile pitri dish with 1X DMEM and mince well (tissue 
should be mushy) 
4. Rinse tissue 3X with 1X DMEM (~20ml/rinse/pituitary) using a scalpel blade as a 
guard to prevent tissue loss into a sterile beaker 
5. Place tissue in a sterile Erlenmeyer flask containing 75ml of 0.3% Collagenase 
Solution and incubate in a 37°C water bathe while gently stirring with a magnetic stir 
bar for 90 minutes 
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6. Filter dispersed cells through double thickness of sterile gauze into a sterile 150ml 
beaker 
7. Transfer cell suspension to 50ml sterile conical tubes and centrifuge for 15 minutes at 
1000 x g 
8. Decant supernatant and resuspend pellets with 1X DMEM using a 10 ml pipette 
9. Pool the suspension and bring to 50 ml, centrifuge at 1000 x g for 15 minutes 
10. Remove supernatant, resuspend pellet (3X) 
11. Resuspend pellet with 20 ml 10% Serum Media 
12. Perform cell counts using a hemacytometer and dilute to 300,000 cells/mL with 10% 
Serum Media 
 
Cell Plating and Treating 
1. Incubate plated cells in 10% Serum Media in 6-well plates for 96 hours 
2. Replace media with fresh 10% Serum Media at hours 48 and 72 
3. Replace media with 1x DMEM media + L-glutamine at hour 96 
4. Wash plated cells with 1x DMEM media + L-glutamine at hour 120 twice 
5. Apply treatment in 1x DMEM media + L-glutamine 
6. Collect media 4 hours post treatment initiation and store in microcentrifuge tubes at    
-20°C  
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Reagents 
1X DMEM (500 ml)       Volume 
100X MEM non-essential amino acids 10 mM   5 ml 
50X MEM amino acids w/o L-glutamine    5 ml 
Fungizone (amphotericin-B 250 µg/ml)    0.5 ml 
Pen-Strep (Pen 10,000 U/ml, Strep. 10,000 µg/ml)   0.5 ml 
NaHCO3 44 mM       1.85 g 
HEPES 15 mM       1.85 g 
1X Dulbecco’s Modified Eagle Medium    bring to 500 ml 
pH solution to 6.8, filter w/0.2 µm sterile filter into sterile bottle 
 
0.3% Collagenase Solution (75 ml)     Volume 
Collagrenase Type L       0.225 g 
1X DMEM        bring to 75 ml 
Filter w/0.2 µm sterile filter into sterile bottle 
 
10% Serum Media (100 ml)      Volume 
1X DMEM        89 ml 
L-glutamine        1 ml 
Fetal Bovine Serum       10 ml 
Filter w/0.2 µm sterile filter into sterile bottle  
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Isotopic in situ hybridization of frozen sections 
Day 1 – Hybridization 
Dry Slides  10 min 55°C 
4% PFA in 0.1M PB 15 min  RT 
0.1M PB 2 X 5 min  
Protienase K (0.5 µg) 
in 0.5 mM EDTA, 50 
mM Tris-HCL 
30 min  37°C 
0.1M PB 1 X 5 min RT 
4% PFA in 0.1M PB 5 min RT 
0.1M PB 1 X 5 min  
Dip in RNase Fee 
Water 
2 X   
Dip in 0.1 M TEA 1 X  
0.1 M TEA + Acetic 
Anhydride 
1 X 10 min 250ul/100ml TEA; 
add to dish first, then 
TEA 
2X SSC 1 X 5 min  
70% 1 X 3 min  
95% 1 X 3 min  
100% 1 X 3 min  
Chloroform 1 X 5 min  
100% 1 X 3 min  
95% 1 X 3 min  
70% 1 X 3 min  
Air Dry Slides   
Pre-Hybridization 1 hrs 37°C 
 
1. Denature radiolabeled probe (1 X 106 cpm/150µl) diluted in hybridization buffer 
containing 100 mM DTT (with DTT added fresh from 1M stock) at 70°C for 10 min 
2. Let hybridization solution cool on ice for 5 min 
3. Add 200µl of hybridization solution to each slide 
4. Cover with parafilm coverslip on each slide - AVOID BUBBLES 
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5. Hybridize overnight at (55°C) in humidified chamber containing Whatman 3MM 
paper wetted with 50% formamide + 5X SSC 
 
Day 2 – Washing 
1. Remove parafilm coverslips from slides and place in 5X SSC without letting slides 
dry 
 
5X SSC with 10mM βME 30 min 55°C 
1X TEN 3 X 10 min 37°C 
RNase (10µg/ml) in 1X 
TEN 
30 min 37°C 
1X TEN 30 min 37°C 
2X SSC with 10mM βME 30 min 55°C 
2X SSC with 10mM βME 15 min 55°C 
0.1X SSC with 10mM βME 15 min 55°C 
0.1X SSC 15 min RT 
   
70% ETOH + 0.3M NH4Ac 2 X 5 min RT 
95% ETOH + 0.3M NH4Ac 3 min RT 
100% ETOH 2 X 2 min RT 
   
 
2. Air dry Slides for (1-3 hr at 37°C) 
3. If needed, Expose slides to film overnight to estimate autoradiography time 
 
Autoradiography 
1. Warm photographic NBT2 emulsion in a light tight container at 44°C in a water bath 
(approx 45 min) 
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2. Warm equal volume of ddH2O to 44°C in a water bath (approx 45 min) 
3. Place a dipping chamber into water bath 
 
In the Dark (with safe-light) 
1. Mix photographic NBT2 emulsion with water in a 1:1 dilution 
2. Pour emulsion into the dipping chamber and let equilibrate to 42-44°C (avoid 
bubbles) 
3. Dip each slide once and withdrawal it slowly (keep the same motion) 
4. Keep slides vertical and wipe excess emulsion from the back of the slide 
5. Let slides to stand up in a rack and air dry for 2-3 hr (place slide rack in a light-tight 
box) 
6. Place slides in a plastic slide box with desiccant 
7. Wrap slide box in double foil to avoid light exposure and place at 4°C for appropriate 
exposure time 
 
Developing Slides 
1. Allow slides to warm to room temperature 
2. Chill Kodak D-19 Developer to 15°C (in fridge or on ice) and dilute 1:1 
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In the Dark (with safe-light, at least 1.5 m from slides) 
1. Place slides into chilled D-19 Developer (diluted 1:1) for 4 min – dip approx 10 
times/min (DO NOT use developer for more than on rack) 
2. Dip in H2O for 30 sec to stop development 
3. Place slides into Kodak Fixer (with hardener, diluted 1:7 with H2O) for 5 min 
4. Dip in H2O for 5 min (can turn lights on) 
 
Coverslipping (counterstain if needed then cover slip) 
1. Dehydrate sections through ETHO 
70% ETOH for 1 min 
95% ETOH for 1 min 
100% ETOH for 5 min 
2. Place slides in Citrosol 3 times for 5 min each 
3. Cover slip with DPX 
 
Reagents 
DEPC-treated H2O (diethilpyrocarbonate H2O) 
ddH2O      1 L 
DEPC      1 ml 
Shake well until foam forms 
Incubate overnight at 37o C 
Autoclave  
 
1 M Phosphate Buffer (10X PB; pH 7.3) – RNase free 
Sodium phosphate dibasic   54.65 g 
Sodium phosphate monobasic  15.9 g 
Depc H2O to final volume of 500 ml 
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0.1 M PB     50 ml  300 ml 
1 M PB     5 ml  30 ml 
ddH2O      45 ml  260 ml 
 
4% Paraformaldehyde (pH 7.2-7.4)  100 ml  300 ml 
Paraformaldehyde    4 g  12 g 
Sodium Hydroxide    ~3g  ~10g 
0.1M PB     100 ml  300 ml 
*Add Sodium Hydroxide to a portion of PB to dissolve first, then add Paraformaldehyde  
*This is just a staring amount of Sodium Hydroxide, add slowly until Paraformaldehyde 
has completely dissolved  
Adjust pH then add remaining PB 
 
1 M Triethanolamine (10X TEA; pH 8) – RNase free 
Triethanolamine     1L  500 ml 
(98%; 149.2 MW; density 1.124 g/ml) 135.5 ml 67.9 ml 
Sodium Chloride    81.8 g  40.9 g  
 
TEA with acetic anhydride   50 ml  300 ml 
0.1 M TEA     50 ml  300 ml 
Acetic anhydride    125 ul  750 ul 
 
1M Tris-HCl (pH 8) – RNase free 
Tris-HCl     78.8 g 
Adjust pH with HCl 
DEPC H2O to final volume of 500 ml 
Autoclave 
 
0.5mM EDTA, 50mM TRIS-HCL  100 ml 
0.5M EDTA     100 ul 
1 M TRIS-HCL    5 mL 
DEPC water to 100ml 
0.5mM EDTA, 50mM TRIS-HCL with 0.5 µg of Protenaise K 
 
Protenaise K plus EDTA, TRIS-HCL 50 ml 
Protenaise K     1.25 ul 
0.5mM EDTA, 50mM TRIS-HCL  to 50 ml 
 
20X Sodium Chloride Sodium Citrate (20X SSC) – RNase free 
Sodium Citrate    88 g 
Sodium Chloride    175 g 
DEPC H2O to final volume of 1 L 
Autoclave  
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5X SSC – 1 L 
250 ml 20X SSC 
750 ml DEPC ddH2O 
 
2X SSC – 1 L 
100 ml 20X SSC 
900 ml DEPC ddH2O 
 
0.1X SSC – 1 L 
5 ml 20X SSC 
995 ml DEPC ddH2O 
 
10X Tris-EDTA-Sodium Chloride (TEN; 1L) – RNase free 
NaCl      292.2 g 
Tris-HCl     100 ml 1 M Tris-HCl (pH 8) 
EDTA      100 ml 0.5 M EDTA (pH 8) 
DEPC H2O to final volume of 1 L 
 
RNase A (10 ug/ml) in 1X TEN  50 ml 
RNase A (20 ug/ml)    25 ul 
1X TEN     to 50 ml 
 
Pre-hybe 4X SSC, 50% formamide  50 ml  300 ml 
20X SSC     10 ml  60 ml 
Deioniezed Formamide   25 ml  150 ml 
DEPC water     15 ml  90 ml 
 
0.5 M EDTA (pH 8) RNase free 
Ethylene diamine tetraacetate   93.05 g 
NaOH pellets     12g 
DEPC H2O to final volume of 500 ml 
Warm to dissolve – must be at pH 8 to stay in solution 
Adjust pH with NaOH pellets 
Autoclave 
 
5M NaCl     500 ml 
NaCl      146.1g 
ddH2O      to 500 ml 
Autoclave  
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3 M Sodium Acetate, pH 5.2   100 ml 
Sodium Acetate    40.81 g 
RNase Free water    80 ml 
pH with glacial acetic acid 
RNase Free water    to 100 ml 
Autoclave 
 
1M DTT     10 ml 
DTT      1.545 g 
0.01M Sodium Acetate pH 5.2  10 ml 
Filter sterilize, and make 1 ml aliquots 
Store at -20°C 
 
5M NH4AC     500 ml 
NH4AC (FW 77.08)    192.7g 
ddH2O      to 500 ml 
 
TE pH 8.0     1 L 
1M Tris, pH 8.0    10 ml 
0.5M EDTA, pH8.0    2 ml 
ddH2O      to 1 L 
 
Hybridization Buffer (RNase free)  Final  Make 50 ml 
Deionized Formamide   50%  25 ml of 100% 
NaCl      0.3 M  3 ml of 5 M stock 
Tris-HCl (pH 8)    20 mM 1 ml of 1 M stock 
EDTA (pH 8)     5 mM  0.5 ml of 0.5 M stock 
NaPO4 (pH 8)     10 mM 0.5 ml of 1 M stock 
Denhardt’s solution    1X  1 ml of 50X stock 
*Dextran Sulfate    10%  5 g (dilute in H2O before  
adding) 
Yeast tRNA     0.5 mg/ml 2.5 ml of 10 mg/ml stock 
DEPC H2O       q.s. (to final volume; ~ 10 
ml) 
*Add ~10ml of water to conical tube, then add Dextran Sulfate.  Mix this first before 
adding other reagents.  
Before use, add 1 M DTT to a final concentration of 100 mM DTT for 35S-labeled 
probes 
 
Yeast tRNA (10mg/ml) 
Yeast tRNA (25mg) 
Dilute 25mg (one vial) in 2.5 ml sterile water 
Incubate for 1 hour at RT 
Aliquot and Store at -20˚C 
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50X Denhardt’s Solution (RNase free) Final   Make 100 ml 
Ficoll 400     1%   1 g 
Polyvinylpyrrolidone    1%   1 g 
BSA (Fraction V)    1%   1 g 
DEPC Water        q.s. (to final volume) 
 
RNase A 
RNase A, 50mg vial  one vial 
TE     2.5 ml 
Mix in vial then aliquot 
Store at -20˚C  
 
Cresyl Violet 
5 g cresyl violet (Sigma C-1791) 
0.5 g sodium acetate 
Dissolve in approximate 800 ml ddH2O 
Adjust pH to 3.5 with glacial acetic acid 
Adjust to final volume of 1 L 
Filter 
Adjust pH to 3.13 to 3.14 with acetic acid 
* Obs: cresyl violet solution should be filtered before each use 
 
10X Acetate Buffer 
2.5 g sodium acetate (MW 136.08) 
Dissolve in approximately 450 ml dd H2O 
Adjust pH to 3.5 with glacial acetic acid (approx 20 ml) 
Adjust final volume to 500 ml 
 
Acidified 70% Ethanol 
10 ml acetic acid 
490 ml 70% Ethanol 
 
All solutions and dishware must be RNase Free 
